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Abstract
Current interventional pharmaceutical therapies targeted for depression are not adequate
to achieve sufficient remission following treatment. Researchers explored inflammatory
biomarkers as a way of understanding why treatment for depression is effective for some
and not others. The purpose of this secondary data analysis study was to determine if
there was a relationship between inflammatory biomarkers and treatment efficacy in
persons diagnosed with depression who have demonstrated a previous lack of remission.
Using the immune-cytokine paradigm of depression (POD) allowed depression to be
viewed as multifaceted and a potential signal of chronic immune system activation. This
secondary data analysis included findings from a clinical trial called, “A Study of the
Efficacy and Safety of CP-601,927 Augmentation of Antidepressant Therapy in Major
Depression.” ANOVA and linear regression were used to analyze 1 dependent variable:
depression remission. The 5 independent variables included adiponectin C-Reactive
Protein (hs-CRP), leptin, interleukin 1-β (IL1-β), interleukin 6 (IL6), and tumor necrosis
factor-α (TNFα). The 3 mediating variables included age, race, and gender. According to
the results of the study, IL6 significantly correlated with and predicted remission
outcome, as measured by change in MADRS total score from baseline. None of the other
biomarkers significantly correlated with remission outcome. Better remission outcomes
for patients suffering from depression would lead to positive social change and improved
quality of life.
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Chapter 1: Introduction to the Study
Introduction
In the United States, depression is one of the most common mental disorders
affecting adults. In 2014, 6.7% of all U.S. adults had at least one major depressive
episode (National Institute of Mental Health [NIMH], 2016b). Despite the prevalence of
this condition, treatment options continue to vary in efficacy (Fava & Rush, 2006;
Lopresti, Maker, Hood, & Drummond, 2014; Strawbridge et al., 2015). Researchers
looked to inflammatory biomarkers as a way of understanding why treatment for
depression was effective for some and not others (Krishnadas & Cavanagh, 2012; Roy &
Campbell, 2013). In this study, the influence of inflammatory biomarkers on treatment
efficacy and remission was examined. Data relating to the influence of inflammatory
biomarkers and depression treatment efficacy has the potential to inform which
pharmacotherapies should yield the greatest benefit to which subpopulation suffering
from depression (Hashimoto, 2015; Strawbridge et al., 2015). Research in this area could
lead to better remission outcomes for patients suffering from depression as a direct result
of doctors’ abilities to tailor treatments to their patients.
For this chapter, several topics are discussed to further expound on the research
topic. The organization of the chapter is comprised of the following: (a) background of
the study, (b) problem statement, (c) purpose of the study, (d) research questions and
hypotheses, (e) conceptual framework, (f) nature of the study, (g) definitions, (h)
assumptions, (i) scope and delimitations, (j) limitations, and (k) significance of the study.
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The chapter ends with a summary of the chapter and an overview of the contents of the
rest of the dissertation.
Background
Depression, even in severe cases, is considered a treatable condition (NIMH,
2016a). However, people are affected differently by depression, and treatment can often
take a trial and error approach, using medications, psychotherapy, or electroconvulsive
therapy (NIMH, 2016a). Depression is considered a highly heterogeneous disease, for
which alternative approaches to investigating new therapies should be considered
(Kennedy & Risvi, 2009).
Treatment
Options for treatment of depression include antidepressants, exercise, alternative
medicine, and psychological interventions. These treatment options can even be
combined. However, many patients are treated for depression by primary care physicians
and are likely to receive a prescription for an antidepressant. Antidepressants work by
selectively targeting neurotransmitters, such as serotonin reuptake inhibitors, serotonin,
and norepinephrine reuptake inhibitors (Gartlehner et al., 2016; Steidtmann et al., 2013).
These medications usually take between 2 and 4 weeks to become effective and are taken
for a duration of 6 to 12 months (NIMH, 2016a).
Remission
The largest clinical trial ever conducted in depression, STAR*D, showed that
remission rates in the study clinics were lower than expected, suggesting the need to
establish several steps to achieve remission for most patients (Gaynes et al., 2009). Both
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switching and augmenting antidepressant therapies appeared reasonable options when an
initial antidepressant treatment failed; however, these two strategies could not be directly
compared (Gaynes et al., 2009; Strawbridge et al., 2015). There is an unmet need to
develop novel approaches to therapeutic strategies for interventions targeted for
populations diagnosed and suffering from depression to enhance treatment outcomes in
depression (Fava & Rush, 2006; Lopresti et al., 2014; Strawbridge et al., 2015).
Although there was a correlation between biomarkers and depression,
inflammatory biomarkers might play a role in the pathophysiology of depression,
warranting investment in further investigation (Krishnadas & Cavanagh, 2012; Roy &
Campbell, 2013). Increased concentrations of inflammatory biomarkers might predict a
lack of response to therapeutic interventions, which might circumvent the mechanisms of
action of conventional antidepressants (Raison et al., 2013). Dysregulation of the immune
system and increased activation of the inflammatory response system that accompanies
depression may provide predicative response cues to the level of efficacy response
(Dowlatia et al., 2010). The symptoms of depression and activation of an inflammatory
response have the potential to alter the remission outcome following intervention with
standard therapies targeted for depression (Miller, Freedland, Carney, Stetler, & Banks,
2003). Characterization of and profiling of inflammatory biomarkers may also present an
opportunity to identify populations diagnosed with depression for other high risk diseases
(e.g., cardiovascular diseases; Zeugmann, Quante, Heuser, Schwarzer, & Anghelescu,
2010). Essentially, although inflammatory biomarkers play a role in the etiology of
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depression, these may also contribute to therapeutic response (Maes, Mihaylova, Kubera,
& Ringel, 2012).
Problem Statement
Current interventional pharmaceutical therapies targeted for depression are not
considered adequate enough to achieve sufficient remission following treatment
(Hashimoto, 2015; Slavich & Irwin, 2014; Wray et al., 2012). Depression yields a burden
regarding adverse symptomatology, decreased productivity, and increases in morbidity
(Wray et al., 2012). Moreover, depression contributes to the facilitation of rising
mortality as a result of suicide (Wray et al., 2012). In clinical trial data examining
outcomes in depression, scholars have historically demonstrated that achievement of
remission is decreasing (Gartlehner et al., 2016; Gaynes et al., 2009; Steidtmann et al.,
2013). Such data indicate that a need to implement strategies that adequately stratify
subpopulations to determine among which groups remission rates are decreasing and to
examine how remission outcomes can be successfully met for these groups (Gaynes et
al., 2009; Lopresti et al., 2014). The problem researched by this study was the
relationship between inflammatory biomarkers and treatment efficacy for depression.
These inflammatory biomarkers respond to the psychosocial stressors associated with
depression, and these both precede and follow diagnosis with major depressive disorder
(Miller & Raison, 2016).
Inflammatory biomarkers, such as adiponectin, hs-CRP, leptin, IL1-β, IL6, and
TNFα affect the effectiveness of newly developed antidepressants. Research efforts
investigating the role biomarkers played in depression also have the potential to inform
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which pharmacotherapies should yield the greatest benefit to the subpopulation suffering
from depression (Hashimoto, 2015; Strawbridge et al., 2015).
Drug development researchers have not examined the role of biomarkers in
identifying populations affected with depression for inclusion in clinical trials (Gaynes et
al., 2009). This study might add insight into the relationship between biomarkers and
treatment efficacy, thereby improving treatment options and outcomes. The role of
inflammatory biomarkers in the etiology of depression was characterized; however, how
this translated to therapeutic outcomes remained unclear (Strawbridge et al., 2015). The
Montgomery Åsberg Depression Rating Scale (MADRS) total score was used to measure
efficacy. The results of this research might help clinicians and scientists to increase
remission rates by increasing understanding of the role inflammatory biomarkers played
in whether the drug worked, potentially fostering achievement of remission.
Purpose of the Study
The purpose of this secondary data analysis study was to determine if there was a
relationship between inflammatory biomarkers and treatment efficacy in persons
diagnosed with depression who have demonstrated a previous lack of remission. I
analyzed an existing dataset from a sponsored experimental, randomized, double-blind,
placebo-controlled, and institutional review board (IRB)-approved clinical trial with the
purpose of identifying relationships between the inflammatory biomarkers and depression
treatment efficacy, depression remission outcomes, and depression treatment response.
These data were analyzed using a multiple linear regression analysis, while controlling
for the demographic variables of age, race, or gender in persons diagnosed with

6
depression. The theory guiding this research was the immune-cytokine paradigm of
depression (POD; Smith, 1997), as it provided a framework for understanding how
depression was a multifaceted condition and a signal of chronic immune system
activation (Smith, 1997).
Research Questions and Hypotheses
Based on the immune-cytokine POD and lack of research on inflammatory
biomarkers in mental health, the following included research questions and associated
hypothesis:
RQ1: Is there any relationship between inflammatory biomarkers, including
adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα and treatment efficacy in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H1o: There is no relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
H1a: There is a relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
RQ2: Is there any relationship between remission outcomes, as measured by
MADRS uniform for each inflammatory biomarker in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS?
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H2o: There are no relationships between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
H2a: There is a relationship between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
RQ3: Is there any relationship between treatment response, as measured by the
MADRS, and inflammatory biomarkers mediated through age, race, or gender in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H3o: There is no relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
H3a: There is a relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
Theoretical Framework for the Study
The immune-cytokine POD (Smith, 1997) was used to support the research on
inflammatory biomarkers and depression treatment efficacy. This framework provides a
mechanism to search new areas for causes of depression (Roy & Campbell, 2013; Smith,
1997). There are four central tenets of this paradigm:
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1.

There is two-way communication between the brain and the immune
system, whereby the immune system can affect the brain (via excretion of
cytokines) and the brain can affect immune system function.

2.

The immune system has two-way communication with the endocrine
system, which is important because endocrine activation is common in
depression.

3.

Physical stressors (infection, trauma, cancer, organ dysfunction, etc.)
activate the immune system and the secretion of cytokines by the brain.

4.

Mental stressors have the same affects as physical stressors. This
framework is useful for this study because depression could be thought of
as multifaceted and a signal of chronic immune system activation. (Smith,
1997)

Understanding the role of inflammatory biomarkers regarding treatment through
the immune-cytokine POD lens potentially revealed other factors in chronic depression
and their correlating treatments.
Nature of the Study
This research study was a quantitative secondary data analysis from an existing
dataset from a sponsored experimental, randomized, double-blind, placebo-controlled,
and IRB-approved clinical trial (ClinicalTrials.gov Identifier: NCT01098240). I focused
on the comparison of an add-on novel pharmacotherapy and placebo in a population
diagnosed with depression who demonstrated a previous lack of remission.
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This secondary data were used to determine if any correlational relationship
existed between the variables of inflammatory biomarkers and treatment efficacy. The
quantitative design was useful for addressing the research questions because I assumed a
narrow-angle lens that focused on testable hypotheses. Executing a post hoc, secondary
data analysis on a randomized controlled trial design assisted me in determining how the
intervention (i.e., the novel pharmacotherapy) influenced the observed outcome (i.e., the
level of efficacy achieved) in those diagnosed with depression (West & Spring, 2010).
Employing a randomization process statistically specified the number of participants to
inform allocation to either the intervention (i.e., the novel pharmacotherapy) or control
(i.e., placebo) group. This approach minimized the systemic differences between these
groups, as these related to both observed and unobserved variables, ensuring internal
validity remained conserved (West & Spring, 2010).
Definitions
Depression: Depression is a mood disorder that affects how a person thinks and
feels, as well as his or her ability to complete daily activities such as eating, sleeping, or
working. The symptoms of depression must be persistent for 2 weeks or more to result in
a diagnosis of depression. Forms of depression include persistent depressive disorder,
perinatal depression, psychotic depression, seasonal affective disorder, disruptive mood
dysregulation disorder, and premenstrual dysphoric disorder (NIMH, 2016a).
Inflammatory biomarkers: Acute and chronic inflammatory responses in the body
are largely the result of cytokines (Brenner et al., 2014). Cytokines are small proteins that
are secreted from cells that can serve as proinflammatory or antiinflammatory agents.
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The term cytokines is a general name for these proteins; examples of cytokines include
adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα (Zhang & An, 2007). Cytokines are
believed to be at the core of depression due to the influence on neuropsychiatric
symptoms and interrelatedness with the immune system, brain, and endocrine system
(Smith, 1997).
Remission: Remission, regarding depression, is traditionally defined
phenomenologically. It is generally defined based on a score on a standardized scale,
such as the Hamilton Rating Scale for Depression; however, patients’ return to their usual
self and usual level of functioning can also be considered (Zimmerman et al., 2014).
Assumptions
To conduct this study, I made several assumptions. These assumptions related to
the validity of the secondary data included in the study, the study of the biomarkers
identified in this study, and the use of the identified conceptual framework. Additionally,
it was assumed that the original study was conducted based upon ethical standards and
principals for the conduct of clinical research. Given the context of the study, these
assumptions were necessary and critical to the study.
Validity of Data
The data used in this study were collected by Pfizer, Inc. during a clinical study,
which was conducted at 25 research centers in the United States between June 2010 and
September 2011. Because I used secondary data and not primary data collected by the
researcher, I assumed that the researchers who originally collected these data took
measures to ensure the validity of the data. This validity included the accurate
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measurement of the identified biomarkers, as well as the accurate measurement of
depression remission using the MADRS.
Conceptual Framework
The conceptual framework selected for this study was the immune-cytokine POD
(Smith, 1997). According to this framework, cytokines play an active role in the presence
and subsequent remission of depression due to the influence on the brain, the immune
system, and the endocrine system and reaction to physical stressors. Because this was a
relatively new perspective from which to view the development and treatment of
depression, there was a need for additional research in this area to support its validity in
both identification and measurement (Brenner et al., 2014). Therefore, I assumed that this
conceptual framework was an appropriate lens through which to view and conduct this
study.
Inflammatory Biomarkers
Cytokines is a generic term for the variety of inflammatory biomarkers that are
present in the body. There are many of these biomarkers, and these play a variety of roles
in the process of inflammation (Brenner et al., 2014). I assumed that the biomarkers,
measured in the data included in this study, were appropriate biomarkers to include in the
discussion of depression and its treatment. I also assumed that the results from the study
involving these specific biomarkers were sufficient for the purpose of applying the results
and findings to the research on depression and inflammatory biomarkers as a whole.
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Scope and Delimitations
This research study was a quantitative secondary data analysis from an existing
dataset from a sponsored experimental, randomized, double-blind, placebo-controlled,
and IRB-approved clinical trial (ClinicalTrials.gov Identifier: NCT01098240). I focused
on the comparison of an add-on novel pharmacotherapy and placebo in a population
diagnosed with depression who demonstrated a previous lack of remission.
The scope of this research study remained limited to the data included in the
described data set from a clinical study conducted by Pfizer, Inc. between June 2010 and
September 2011. Study participants consisted of outpatients between the ages of 18 and
65 years. The research study remained delimited to the examination of the correlations of
the biomarkers; adiponectin; hs-CRP; leptin; IL1-β, IL6; TNFα; depression treatment
efficacy; depression remission; and the demographic factors of age, race, and gender.
Other theoretical and conceptual frameworks considered for this study included
the affective response model (Zhang & An, 2013) and the social signal transduction
theory of depression (Slavich & Irwin, 2014). The affective response model relates to the
emotional aspects of depression, not the biological processes that occur with this
disorder. The social signal transduction theory of depression involved the biological
responses to major life stressors, which I could not measure using the data included in
this study. Consequently, the immune-cytokine POD (Smith, 1997) was the most
applicable conceptual framework for this study, especially given the study’s purpose,
research questions, and data. Results of this study would potentially be generalizable, as
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these related to the demographic of adults aged 18 to 65 and specifically relating to the
biomarkers outlined in this study.
Limitations
This study remained limited as it related to data, the scope of the research, and the
chosen research design. The data, selected for this study, were secondary data; therefore,
the data were limited to the variables that were already included in this study. Another set
of data would need to be collected to examine other variables related to inflammatory
biomarkers and depression treatment and remission. Similarly, the scope of the research
was limited by the chosen data set. Even though there were many inflammatory
biomarkers, the study was limited by the inflammatory biomarkers that were already
included in this study. If other biomarkers were to be examined, a new data set would
have to be acquired and examined. Finally, the research design was correlational using a
multiple linear regression analysis. Consequently, correlation did not imply causation;
therefore, this study was limited to examining the relationships between variables rather
than identifying causation.
Significance of the Study
Depression is a public health concern for the United States and for the entire
world (Johansson, Lundh, & Bjärehed, 2015). Even though standard treatments for
depression can be effective, almost two-thirds of patients suffering from major depressive
disorder do not respond to treatment using pharmaceuticals (Hashimoto, 2015). This
study was significant because it advanced theory, advanced practice, and could lead to
positive social change as it relates to understanding and treating depression.
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Significance to Theory
The theoretical foundation chosen for this study was the immune-cytokine model
of depression (MOD). This theory is a relatively new way of understanding how physical
and mental disorders are related (Smith, 1997). This study was significant to supporting
immune-cytokine MOD, as well as paving the way for extensions of this theory in the
future. In this study, I sought to identify relationships between cytokines (i.e.,
inflammatory biomarkers) and treatment outcomes for depression. Any results from this
study relating to the correlations between these biomarkers and treatment outcomes could
help to defend or refute the immune-cytokine theory and help to narrow down the
biomarkers more closely related to treatment outcomes compared to others. Additionally,
these results could help to narrow the research gap so that future researchers could begin
to identify the extent of identified relationships, hypothesize causation, and develop maps
of the sequencing of chain reactions between the physical and mental processes that
result in the development or remission of depressive disorders.
Significance to Practice
Researchers have described treatment outcomes for depression as “modest” at
best (Steidtmann et al., 2013, p. 784). Doctors have used a combination of
pharmacotherapy, psychotherapy, and other strategies to achieve the best results for
patients, but these treatments are often the result of trial and error. This study was
significant to practice because information relating to inflammatory biomarkers and
treatment outcomes could assist in prescribing the right treatment for patients the first
time. Data, such as from this study, could help doctors to tailor treatments to patients
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based on the inflammatory biomarkers that have been presented. This type of treatment
could save practitioners time and help to increase their patient success rates and
satisfaction.
Significance to Social Change
Researchers have described depression as a “public health burden” (Abel, Hayes,
Henley, & Kyyken, 2016, p. 726). Depression costs the United States billions of dollars
annually (Greenberg, Stiglin, Finkelstein, & Berndt, 1993). In addition, persons suffering
from depression are more likely to commit suicide. Information and data that can assist in
more effectively treating depression can lead to positive social change. This study was
significant because it could help to narrow the gap in understanding how physical
conditions were related to mental conditions as these conditions relate to depression. This
information could lead to development of early identification of depressive symptoms,
more effective treatment of depression, and the prevention of depression. This could
ultimately lead to reduce rates of suicide and reduced medical spending for families and
the United States as a whole.
Summary
Depression is of concern in the United States and worldwide. Despite many
treatment strategies for depression, there are low rates of continued remission for
patients. The emergence of research relating to inflammatory biomarkers is promising in
that it can fill in the gaps between understanding how human physical and mental process
are related. The purpose of this secondary data analysis study was to determine if there
was a relationship between inflammatory biomarkers and treatment efficacy in persons
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diagnosed with depression who have demonstrated a previous lack of remission. This
chapter has provided information relating to the background of this study, the study
problem, and the significance of this study. Chapter 2 contains a review of current and
seminal literature relating to the study problem.
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Chapter 2: Literature Review
The problem researched by this study was the relationship between inflammatory
biomarkers and treatment efficacy for depression. These inflammatory biomarkers
respond to the psychosocial stressors associated with depression, and these both precede
and follow diagnosis with major depressive disorder (Miller & Raison, 2016). In clinical
trial data examining outcomes in depression, scholars have historically demonstrated that
achievement of remission is decreasing (Gaynes et al., 2009). There is a need to
implement strategies that adequately stratify subpopulations to determine among which
groups remission rates are decreasing and to examine how remission outcomes can be
successfully met for these groups (Gaynes et al., 2009; Lopresti et al., 2014).
The role of inflammatory biomarkers in the etiology of depression have been
characterized; however, how this translated to therapeutic outcomes remained unclear
(Strawbridge et al., 2015). The results of this research might help clinicians and scientists
to increase remission rates by increasing understanding of the that role inflammatory
biomarkers played in whether the drug worked, potentially fostering achievement of
remission (Strawbridge et al., 2015). The results of this study provided information on the
treatment of depression and the predictors thereof.
The purpose of this quantitative, secondary analysis study was to determine
whether there was an association between inflammatory biomarkers and treatment
efficacy. I also examined if remission outcomes were uniform for each inflammatory
biomarker and attempted to determine whether there was an association between
treatment response and inflammatory biomarkers mediated through age, race, or gender.
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Literature Search Strategy
The databases accessed to locate the needed literature and published research for
this chapter included Google Scholar, DeepDyve, and ERIC. Search terms included the
immune-cytokine model of depression, inflammatory biomarkers, treatment efficacy,
depression, inflammatory biomarkers in depression, remission, treatment, age, gender,
race, biomarkers, MDD, definition of depression, and combinations of these terms. To
obtain the most current research, sources were prioritized to show literature published
within the last 4 years.
Studies believed relevant were included in this chapter. Of the 75 sources
obtained for this chapter, 64 articles (85.3%) were published between 2012 and 2016, and
11 articles (14.7%) were published prior to 2012. Types of literature included peerreviewed articles, clinical trials, and previous studies. All sources were published in peerreviewed journals. Few concrete studies and articles are available on the effects of
inflammatory biomarkers on the treatment efficacy and remission outcomes of patients
diagnosed with depression. Therefore, I provided discussion of other studies regarding
different treatments of depression, remission outcomes, as well as other theories on
depression.
Theoretical Foundation
Depression has been a topic of discussion for decades because so many
contradicting views on its cause and effects exist. The theoretical foundation chosen for
this study was the immune-cytokine MOD, a new theoretical concept, as a means to
understand depression. The immune-cytokine MOD bridged the gap between physical
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and mental disorders. According to the immune-cytokine MOD, depression is a chronic
physical-biological disorder with mental-emotional symptoms (Smith, 1997).
The immune-cytokine MOD was used to support the research on inflammatory
biomarkers and depression treatment efficacy. This framework provided a mechanism to
search new areas for causes of depression (Roy & Campbell, 2013; Smith, 1997). There
are four central tenets of this paradigm. First, there is two-way communication between
the brain and the immune system, whereby the immune system can affect the brain (via
excretion of cytokines), and the brain can affect immune system function (Smith, 1997).
Second, the immune system has two-way communication with the endocrine system,
which is important because endocrine activation is common in depression. Third,
physical stressors (e.g., infection, trauma, cancer, organ dysfunction, etc.) activate the
immune system and the secretion of cytokines by the brain. Finally, mental stressors have
the same effects as physical stressors (Smith, 1997).
From an immunological perspective, cytokines are the core of depression because
they cause a plethora of neuropsychiatric symptoms (Smith, 1997). During the 1980s,
researchers proved the acute consequences of cytokines on the mood, thought, and
behavior of human volunteers. Molecules that are produced by the human body, when
taken by humans, results in the symptoms of a depression diagnosis (Smith, 1997). The
research was of significance, although psychologists and psychiatrists were not interested
in discoveries coming from other fields, such as immunology (Smith, 1997). The
immune-cytokine MOD provided a two-way system since 1982. The immune system, via
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the secretion of cytokines, can affect brain function (Smith, 1997). There are several
different substances known as cytokines. These cytokines are discussed individually.
Interferon-Alpha (INFα)
When monocytes and macrophages are activated, it releases the interferon-alpha
(INFα) cytokine. This cytokine provides many benefits for various immune cells,
although still carrying various hampering neuropsychiatric effects. Priestman (1980)
reported on the effects of interferon-alpha in 1980, and Rohatiner et al. followed in 1983.
Rohatiner et al. (1983) studied 11 human subjects. After giving the volunteers
Interferon-alpha intravenously for 7 days, all volunteers felt feverish and fatigued, and
they lacked appetite. They also slept a lot, appeared antisocial, were slow to answer
questions, and lacked interest in their surroundings (Rohatiner et al., 1983). The abnormal
brain waves of the volunteers were similar to those of patients with a brain degenerative
disease (Rohatiner et al., 1983). These volunteers could be diagnosed with a major
depressive episode after only 1 week. Adams, Quesada, and Gutterman (1984) also
studied the effects of interferon-alpha over 4 weeks. As with the abovementioned study,
the volunteers also exhibited symptoms of severe depression, although a depressed mood
was not present (Adams et al., 1984). It proved that interferon-alpha provokes the
symptoms of depression, as well as fits in with the diagnostic paradox (Smith, 1997).
Tumor Necrosis Factor (TNF)
Monocytes, macrophages, and lymphocytes secrete TNF. The properties of TNF
are similar to interleukin1, as it can regulate several organs including the brain. The
symptoms of TNF on human volunteers, when given intravenously, include fatigue,
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anorexia, headaches, muscle ache, and discomfort (Smith, 1997). The symptoms are
similar to those of major depression. Headaches are a symptom of many cytokines, but it
appears more significant to TNF (Smith, 1997).
Interleukin1 (IL1)
Monocytes and macrophages secrete IL1, and its effects have only been tested on
animal subjects. During trials, the animals exhibited symptoms, such as anorexia, reduced
activity, loss of interest in usual activities, discomfort, increased sleep, lack of body care
activities, reduced social exploration, and less food-motivated behavior (Smith, 1997).
These symptoms mimic the symptoms familiar with depression in humans. In another
study, Smith (1997) found that stressful social situations, in combination with IL1,
caused irritable and hostile behavior of monkeys. This type of behavior also associated
with depression (Smith, 1997).
Interleukin-2 (IL2) and Interferon-Gamma (INFγ)
T-lymphocytes secrete INFγ and IL2; low doses of IL-2 produce symptoms of
depression, including lethargy, impaired memory, slowed responses, impaired attention,
anorexia, lack of interest, and irritability. High doses of IL2 result in hallucinations,
delusions, and disorientation, which are associated with schizophrenia. INFγ results in
symptoms of fatigue, discomfort, headaches, lack of appetite, weight loss, weakness,
lethargy, and decreased concentration, all of which are associated with depression in
humans (Smith, 1997).
The abovementioned cytokines have the ability to result in symptoms of
depression for most subjects but not all. Cytokines, such as INFα, INFγ, TNF, and IL2,
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did not result in depression for all subjects. Taking into account that cytokines are present
in every human body and can be produced at any given time provided the right
simulation, it is fortunate that the secretion of cytokines do not result in depression 100%
of the time. If that was the case, depression rates would be much higher (Smith, 1997).
Furthermore, the experiments only administered one cytokine at a time, which is
inconsistent with natural immune activation (Smith, 1997). Naturally, many cytokines are
produced at the same time, resulting in a much higher risk of depression (Smith, 1997).
This framework was useful for this study because depression is multifaceted and a
signal of chronic immune system activation (Smith, 1997). Understanding the role of
inflammatory biomarkers regarding treatment through the immune-cytokine POD lens
may reveal other factors in chronic depression and their correlating treatments.
Depression is not only multifaceted, but there are also a plethora of variables that
influence treatment administration, as well as treatment outcomes. As inflammatory
biomarkers have been added to the list of variables for depression, a more recent
theoretical framework was needed for optimum analysis.
Literature Review Related to Key Variables and/or Concepts
The number of antidepressants and therapies for depression, which are currently
available, is vast; yet, these do not guarantee remission. Current interventional
pharmaceutical therapies targeted for depression are not considered adequate enough to
achieve sufficient remission following treatment (Hashimoto, 2015; Slavich & Irwin,
2014; Wray et al., 2012). Depression yields adverse symptomatology, decreased
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productivity, and increased in morbidity, as well as contributing to rising mortality
resulting from suicide (Wray et al., 2012).
In clinical trial data on outcomes of depression, scholars have demonstrated that
achievement of remission is decreasing (Gaynes et al., 2009). Cuijpers et al. (2014)
posited that there was a correlation between depression and an elevated risk of death for
patients; although, it was not clear if the cause of this phenomenon was specific to the
disease, patient groups, or a generic result of mortality in certain communities. There is a
need for strategies that adequately stratify subpopulations to determine among which
groups remission rates are decreasing and to examine how remission outcomes can be
successfully met for these groups (Gaynes et al., 2009; Lopresti et al., 2014).
Marrie et al. (2016) have found a correlation between illnesses with an
inflammatory component and depression, which resulted in scholars investigating
depression alongside inflammatory biomarkers. One of these illnesses is inflammatory
bowel disease. Marrie et al. (2016) stated that a correlation existed between depression
and anxiety and inflammatory bowel disease (IBD). Furthermore, Marrie et al. mentioned
that methods aiding population-based studies on depression and anxiety were needed.
Sipido et al. (2016) concluded that depression and anxiety was significantly related to
increased levels of C-reactive proteins, as well as high cholesterol. Sipido et al. posited
that the results of their study were of significance, as these aided in the explanation of
pathophysiological mechanisms connecting depression and anxiety to cardiovascular
disease. More information on these pathophysiological links could assist physicians in
providing more specialized and individualized treatment for patients (Sipido et al., 2016).
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Few researchers have explored the effect of inflammatory biomarkers in adolescence,
even though the effect of inflammatory biomarkers was believed to happen at key stages
in a patient’s life, such as adolescence (Walker et al., 2014). Scholars showed that higher
levels of TNF-α, IL-6, and IL-10 in patients during the early phases of bipolar disorder,
where CRP was found to predict the risk of depression (Walker et al., 2014).
Inflammatory biomarkers have the ability to affect antidepressant treatment
negatively. Inflammatory biomarkers, such as adiponectin, CRP, leptin, IL1-β, IL6, and
TNFα affect the effectiveness of newly developed antidepressants. Investigating the role
biomarkers play in depression also has the potential to inform which pharmacotherapies
should yield the greatest benefit to which subpopulation suffering from depression
(English, Lebovitz, & Griffin, 2010; Strawbridge et al., 2015). Drug development
researchers have not y examined the role of biomarkers in identifying populations
affected with depression for inclusion in clinical trials (Gaynes et al., 2009). Lopresti et
al. (2014) and Strawbridge et al. (2015) might add insight into the relationship between
biomarkers and treatment efficacy, thereby improving treatment options and outcomes.
Inflammatory Biomarkers and Treatment Efficacy
Inflammatory biomarkers as a predictor for depression. More research has
been conducted on the influence of inflammatory biomarkers (inflammatory cytokines)
on mood disorder pathophysiology. These cytokines are also known as proinflammatory
mediators (interleukin 1, IL-6, TNF-α, CRP; Sua, 2012; Walker et al., 2014).
Furthermore, researchers posited that children at the ages of 10 and 15 years, who have
had traumatic experiences between the ages of 1.5 and 8 years, proved to have higher
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levels of CRP and IL-6, which was associated with immune activation and symptoms of
depression (Sua, 2012; Walker et al., 2014). Higher levels of inflammatory biomarkers
have been used to predict the severity of depression and the risk of recurrence in males.
Inflammatory biomarkers could be used to predict mood disorder pathology. Increased
levels of inflammatory biomarkers related to the progression of mood disorders (Sua,
2012; Walker et al., 2014).
Inflammatory biomarkers used for diagnosis. Bredt et al. (2015) stated that the
antidepressants available took weeks to relieve symptoms and that it was often found that
the response of patients fluctuated with time. Mood disorders were one of the most
common diseases (Bredt et al., 2015). Biomarkers have proved invaluable in the
explanation of treatment for diseases, as well as treatment responses of patients (Lopresti
et al., 2014). Incorporating inflammatory biomarkers in the diagnoses and selecting of
treatment for psychiatric diseases would make a difference in a field that had relied on
interviews and questionnaires of patients for evaluation (Lopresti et al., 2014).
Chan et al. (2016) agreed with Bredt et al. (2015) on the available antidepressants
not being optimal, and they added that there was only a 50% response rate in patients.
With all available aids present, allocating the most effective treatment to patients
remained a challenge and happened on a trial and error basis (Chan et al., 2016).
Yohannes and Alexopoulos (2014) also posited their concern with the lack of appropriate
treatment being allocated to patients diagnosed with MDD and anxiety. The symptoms of
these diseases are multifaceted and include social, biological, and behavioral aspects.
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Yohannes and Alexopoulos posited that one of the reasons for this problem was the lack
of a standardized diagnostic approach for inflammatory biomarkers.
Treatments for depression. Patients often do not respond to treatment for
depression; as such, the chances of remission are slim. Ruland et al. (2016) and Sua
(2012) postulated the concerns regarding patients with major depressive disorder (MDD)
who have proved nonresponsive to several treatments and antidepressants, and who then
became treatment resistant as a result of successive unsuccessful treatment. Scholars have
highlighted the urgency of new strategies to ascertain personalized and individualized
treatment for MDD patients (author, year). Biomarkers that could predict treatment
responses would prove a significant tool to allocate the correct treatment (Chan et al.,
2016).
To administer the most effective treatment to patients, researchers conducted
studies to determine the variables that may predict a patient’s response to treatment. Chan
et al. (2016) conducted a study investigating the association of 258 potentially predictive
inflammatory biomarkers regarding treatment response in 332 MDD patients and showed
that a pretreatment immune-endocrine profile could predict a patient’s responsiveness to
an antidepressant or treatment. This would be of assistance to individualized treatment.
Chan et al. investigated tissue inhibitor of metalloproteinases 1, intercellular adhesion
molecule 1, apolipoprotein a-iv, endoglin, thrombopoietin, plasminogen activator
inhibitor 1, hepatocyte growth factor, complement c3, and insulin-like growth factorbinding protein 2 and their response to Venlafaxine, Imipramine, and other antidepressant
drugs. Miller and Raison (2016) stipulated that patients diagnosed with MDD displayed
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all the qualities associated with an inflammatory response, which included higher levels
of proinflammatory cytokines.
Miller and Raison (2016) stated that there was a correlation between
inflammation and depression. Miller and Raison showed that IL-1β, IL-6, TNF, and CRP
have the most significant relation to inflammation in patients diagnosed with MDD.
Regarding treatment response, the presence of high levels of IL-1β, TNF, and CRP have
the most significant predictors. When inflammatory cytokines are introduced to normal
controls, they were found to induce the symptoms of depression (Miller & Raison, 2016).
Miller and Raison showed that by blocking these cytokines, the symptoms of depression
were reduced. Inflammation was correlated with nonresponsiveness to antidepressant
treatment (Miller & Raison, 2016). I stopped reviewing here. Please go through the rest
of your chapter and look for the patterns I pointed out to you. I will now look at your
Chapter 3.
Further studies also sought to determine the correlation between inflammatory
biomarkers and the effect on different therapies of depression. Berk et al. (2015) posited
that there was often a correlation between depressive disorder and physiological changes,
which could affect medical illness, as well as increase proinflammatory cytokines. They
sought to determine the impact of religious cognitive behavioral therapy (RCBT) in
comparison to conventional CBT (CCBT) and the effect these therapies have on
pro/antiinflammatory biomarkers and stress hormones (Berk et al., 2015). The sample
consisted of 132 subjects who had been diagnosed with major depressive disorder (MDD)
as well as a chronic medical illness. They found that RCBT or CCBT had no significant
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effect on change in any biomarkers. CCBT proved more effective in lowering lL-6 in
those with low religiosity, and RCBT was more effective in those with high religiosity
(Berk et al., 2015). The results of this study were of significance, as these results showed
that different therapies related to MDD still had a correlation with inflammatory
biomarkers, however insignificant.
Dowlatia et al. (2010) contradicted Berk et al. (2015). The aim of Dowlatia et al.’s
(2010) quantitative secondary analysis study was to examine the concentrations of
specific cytokines identified in patients diagnosed with a major depressive episode, as the
literature suggested a correlation between depression and immune dysregulation, as well
as the activation of the inflammatory response system (IRS). After a meta-analysis of the
available studies, 24 studies involving unstimulated measurements of cytokines in
patients with major depression were included (Dowlatia et al., 2010). Dowlatia et al.
(2010) showed significantly higher concentrations of TNF-α and IL-6 in depressed
subjects in comparison with control subjects. None of the other cytokines that were
examined showed significant differences between depressed and non-depressed subjects.
This meta-analytic study was significant, as it strengthened the argument of the current
study: Depression correlated with activation of the IRS. The correlation between
inflammatory biomarkers and depression was evident and aided further investigation to
have a concrete understanding of its relationship (Dowlatia et al., 2010).
Individualized depression therapy. The searches for more accurate treatment
with better outcomes for MDD have been vast. As treatment outcomes in patients with
MDD are such a pressing problem, the need for predictive variables has increased. Redei
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et al. (2014) sought to explore the possibility of a laboratory-based diagnostic tool that
could increase the diagnostic accuracy of MDD and determine classifying factors to
provide individualized therapy. Furthermore, Redei et al. (2014) sought to determine
whether inflammatory biomarkers showed a relationship with treatment outcomes in or if
these could be of assistance in such a predictive diagnostic tool. Redei et al. administered
cognitive behavioral therapy (CBT) to 32 MDD patients. Blood samples were taken at
baseline and at the end of 18 weeks. Redei et al. concluded that blood levels of different
transcript panels could predict depression among primary care patients, during a
depressive episode or while in remission, or follow and predict response to CBT. The
results showed the possible presence of biomarkers in the blood of potential MDD
patients. The study was significant, as it correlated with the aim of the study at hand, it
and provided premise for further investigation (Redei et al., 2014).
It is well known that the treatments for anxiety disorders are often ineffective, and
the variables contributing to this outcome should be examined and determined to assist
with individualized treatment. Wolitzky-Taylor, Arch, Rosenfield, and Craske (2012)
posited that one must understand under what circumstances, as well as for whom, in the
sense of biological composition, treatments were most effective. Wolitzky-Taylor et al.
attempted a study to determine the effectiveness of cognitive behavioral therapy (CBT) in
comparison to acceptance and commitment therapy (ACT). Eighty-seven patients
diagnosed with anxiety underwent 12 weeks of either CBT or ACT, and the patients were
measured via a self-report at baseline, after 12 weeks, after 6 months, and after 12
months. The success of CBT was evident when compared to ACT in patients with
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medium anxiety levels at baseline who had no additional mood disorders. ACT had more
success with patients who had been diagnosed with multiple mood disorders (WolitzkyTaylor et al., 2012). There was also a correlation between poorer responses to treatment
and higher measures of neuroticism at baseline. Comorbidity, race, gender, age, or
severity of the disorder were not found predictive of treatment outcomes (WolitzkyTaylor et al., 2012).
Alternative treatments for depression. As the struggle for successful MDD
treatment continues, several alternative treatments have also been studied. Sua (2012)
showed significant results for alternative medication, such as omega-3 supplementation.
Sua posited that one of the most significant clinical trials on the effect of inflammatory
biomarkers and the symptoms of depression included interferon-α-induced depression in
patients with chronic hepatitis C. Sua further posited that alternative options for
antidepressants were being researched, and it included the antiinflammatory pathway, as
well as omega-3 polyunsaturated fatty acids (PUFAs), which were found to have a
natural antiinflammatory and antidepressant effect.
Rapaport et al. (2016) examined the effect of inflammatory biomarkers on omega3 (n-3) fatty acids, and whether it had a mediating effect on patients diagnosed with
MDD. One-hundred and fifty-five subjects were recruited, who were diagnosed with
MDD (according to the Hamilton Depression Rating Scale). The inflammatory biomarker
levels of IL-1ra, IL-6, high-sensitivity hs-CRP, leptin, and adiponectin of the patients
were measured at baseline and at the end of the 8 week treatment and placebo (Rapaport
et al., 2016). Treatment included eicosapentaenoic acid (EPA)-enriched n-3 and
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docosahexaenoic acid (DHA)-enriched n-3 doses per day. Patients were divided into
groups of high and low levels of inflammatory biomarkers (Rapaport et al., 2016).
Patients who fell in the high inflammatory biomarker level group showed more
improvement on EPA when compared to the placebo group. The results for EPA
treatment versus placebo were further separated when higher levels of inflammatory
biomarkers were present (Rapaport et al., 2016). The patients receiving EPA treatment
showed medium decreases on the HRSD scale and showed less response to placebo when
compared to patients with low inflammatory biomarker levels (Rapaport et al., 2016).
The results of this study are significant, as it implies that the level of inflammatory
biomarkers measured in patients may have predictive qualities for treatment outcomes. It
also showed EPA treatment was effective in patients with MDD (Rapaport et al., 2016).
Fond et al. (2013) also discovered the effectiveness of polyunsaturated fatty acids
on MDD patients through a systematic review of the available literature, without any year
or language limitations. Fond et al. specifically researched the efficacy of four major
antiinflammatory drugs (PUFAs, COX, antiTNFalpha, and minocycline) on MDD,
schizophrenia, and bipolar disorders. Fond et al. found specific significance regarding the
effect of these antiinflammatory drugs on MDD. PUFAs were found effective in the
treatment of MDD, and antiTNFalpha proved significant efficacy in specifically
treatment resistant MDD. The various antiinflammatory drugs available, amidst the side
effects, proved valuable alternatives for MDD and treatment resistant MDD (Fond et al.,
2013).
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Carney, Steinmeyer et al. (2016) also echoed the results of PUFA treatment and
its success in relieving the symptoms of depression. Carney, Steinmeyer et al. found that
omega-3 supplementation could be an effective treatment for patients with MDD;
although, the duration and ratio of treatment depended on baseline omega-3 levels of the
patient at hand. Lopresti (2014) tested another alternative treatment using curcumin as an
antidepressant. Lopresti sought to determine the antidepressant effects of curcumin on
patients who have been diagnosed with MDD. The researcher conducted an 8-week,
randomized, double-blind, and placebo-controlled study. Curcumin was administered to
patients at a dose of 500 mg, twice daily. For the first 4 weeks of treatment, curcumin,
and placebo was found equally effective, but from Weeks 4 to 8, curcumin showed
superior antidepressant efficacy. Furthermore, Lopresti sought to determine the potential
effect of inflammatory biomarkers on MDD and to evaluate the effects of curcumin on
these biomarkers. Results showed that biomarkers could enhance diagnosis, predict
treatment progress, and assist in the choice of treatment. Researchers found that urinary
leukotriene B4, thromboxane B2, and substance P had changed as a result of curcumin
treatment (Lopresti et al., 2014). Treatment efficacy was correlated with higher baseline
concentrations of plasma endothelin-1 and leptin. This study provided insight on the
predictors of treatment efficacy, as well as evidence of the correlation between
inflammatory biomarkers, depression, and the treatment thereof (Lopresti et al., 2014).
Other mental illnesses have also been associated with inflammatory biomarkers,
such as anxiety, bipolar disorder, and schizophrenia. Keller et al. (2012) posited that there
was an increase of interest on the association between inflammation and schizophrenia,
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and also the association of inflammatory biomarkers in schizophrenia treatment. Keller et
al. further stated that evidence was increasing regarding the alternative treatments for
schizophrenia, including antiinflammatory treatments. They predicted that the research
on this topic would expand even more within the next few years (Keller et al., 2012).
Loebel et al. (2014) conducted a study on the effects of lurasidone (antipsychotic
agent) in conjunction with lithium or valproate as adjunctive therapy in patients
diagnosed with bipolar and depression. The sample, used for this study, was focused on
patients who have not responded to monotherapy (Loebel et al., 2014). The trial included
6 weeks of the abovementioned therapy for 183 patients and placebo for 165 patients.
The Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global
Impressions scale was used to measure depression and bipolar severity at baseline and at
the end of the trial (Loebel et al., 2014). The effects of lurasidone treatment were
significant in relieving depression as well as bipolar when compared to placebo. There
were also significant improvement on anxiety symptoms, as well as an increase in quality
of life (reported by patients) and functional impairment (Loebel et al., 2014).
Anderson et al. (2012) investigated another treatment option for treatment
resistant depression (TRD). Deep brain stimulation (DBS) was found effective on
symptoms associated with movement disorders. Anderson et al. sought to determine the
effectiveness of DBS on patients with TRD. The study sample was limited, but according
to the literature, there had been great success in the reduction of depressive symptoms, as
well as elevated rates of remission for TRD patients (Anderson et al., 2012). Although
the encouraging results, there remained a lack of understanding in the mechanisms

34
providing the success. More studies should be conducted to identify the variables at play
(Anderson et al., 2012).
Depression is often found as a comorbid disease in patients with inflammatory
illnesses. A correlation between depression and inflammatory bowel disease had surfaced
because recent research has proven depression to be significantly associated with
activated immune-inflammatory, oxidative, and nitrosative stress (IO&NS) pathways
(Martin-Subero, Anderson, Kanchanatawan, Berk, & Maes, 2015). Martin-Subero et al.
(2015) also found that there was an increase in depression manifestation in IBD patients,
which causes increased morbidity, as well as lower quality of life. The cause of
depression manifestation in IBD patients related to an increased level of proinflammatory
cytokines. It seemed that the mechanics of depression and IBD overlap, which could
explain this phenomenon. Martin-Subero et al. further stated that this could have an
implication on the treatment for IBD when depression was also present in a patient
(Martin-Subero et al., 2015).
One could conclude that several treatments existed for the treatment of
depression, and yet the outcomes of these treatments were not full proof. Martin-Subero
et al. (2015) agreed that more research should be conducted to determine the variables,
influencing treatment outcomes, to revolutionize treatment allocations, which would be
most effective according to specific patients. The heterogeneity of depression remained a
reality, and researchers should focus on the cause of it to determine the solution (Kessler
et al., 2016).
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Inflammatory Biomarkers and Remission Outcomes
When patients are diagnosed with depression, it is expected that the process to
remission is lengthy, including several types of treatment including antidepressant drugs
and therapy, and yet remission is still not guaranteed. Fava and Rush (2006) posited that
most patients diagnosed with MDD never reached remission. The severity of depression
in these patients are often much worse compared to patients who are found to remit.
Several treatments and antidepressant drugs are administered to these patients to find an
appropriate and effective treatment to reduce the symptoms, with remission as a longterm goal. Fava and Rush felt that not enough controlled studies had been completed on
the effectiveness of treatments, and clinicians should be more cautious when
administering treatment to give their patients the highest chance of remission. Brent et al.
(1998) found that clinical remission had a positive correlation with self-reported
depression. One could assume that self-perspective played a role in the success of
treatment as well as the chances of remission.
Remission is subjective. The state of remission experienced by patients may be
subjective. This significantly increases the diagnoses and correct treatment of MDD
patients. Zimmerman et al. (2012) posited that the definition of remission from
depression was not well defined. Zimmerman et al. examined the amount depressed
patients, who were in remission according to the HRSD, who did not agree that they were
in remission. Zimmerman et al. further investigated the demographical and clinical
differences of the patients who did or did not agree with their own remission status. In
addition, 274 patients were interviewed over more than a year. The results showed that 77
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of 140 patients who were remitted did not agree with their remission status (Zimmerman
et al., 2012). The patients considered themselves in remission and had considerably lower
levels of depression when compared to the patients who did not consider themselves in
remission. Patients in remission proved to have considerably higher life quality and more
functionality. Patients also had higher levels of mental health, better coping ability, and
were less likely to report dissatisfaction in their mental health. The study proved that
symptoms should not be relied on independently (Zimmerman et al., 2012). A closer eye
should be kept on remission status, and treatment should be adjusted accordingly.
Zimmerman et al. (2012) demonstrated the heterogeneity of depression, the treatments
thereof, and the misconceptions of remission with their findings.
A variable that may also influence MDD patients’ state of remission is their
perspective of remission (Zeng et al., 2016). An extensive quantitative study was
conducted in China to determine the perspective of remission in patients not submitted to
clinics (Zeng et al., 2016). The design of the study was prospective, multi-centered, and
observational. The sample included 9855 patients who were assessed at baseline, Week 2
and Week 4, using the 17-item Hamilton Rating Scale for Depression (HRSD), as well as
the Remission Evaluation and Mood Inventory Tool (REMIT). The patients’ symptoms
and general sense of wellbeing and mental health were assessed (Zeng et al., 2016). The
results showed that 91.3% of patients experienced medium to intense depression.
Zimmerman et al. (2013) found that definite improvement was reported after 4 weeks of
treatment in terms of symptoms, as well as general sense of wellbeing. Zimmerman et al.
determined that more focus on the wellbeing and mental health status of patients would
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provide the patients themselves, as well as clinicians with wider perspective on the health
status of patients.
As the state of remission may be subjective, another study sought to determine the
validity of models that measure depression and remission. A study conducted on 153
patients with MDD to determine the validity of the Remission from Depression
Questionnaire (RDQ) in comparison to the Quick Inventory of Depressive
Symptomatology (QIDS) and 17-item Hamilton Rating Scale for Depression (HRSD)
found that all three of these measures proved correlated and quite accurate (Zimmerman
et al., 2013). The patients were assessed at baseline and after 4 months, and the
researchers postulated that the use of the RDQ might provide more insight on the
remission status of patients, and physicians should use this to their advantage
(Zimmerman et al., 2013).
Diagnostic tools to administer appropriate treatment. Determining predictors
of treatment response would significantly increase the chance of remission for patients
with MDD. Carney, Freedland, Steinmeyer, Rubin, and Rich (2016) sought to determine
if there was a correlation in the predictors for treatment response for patients with major
depressive episode, as well as patients with coronary heart disease (CHD). One-hundred
and fifty-seven patients with CHD and major depressive episode were treated with CBT,
with or without an antidepressant over 16 weeks. At the end of the 16 weeks, over 50%
of the subjects were in remission. The researchers found that depression outcomes were
predicted by severe depression at baseline, stressful life events during treatment, and the
completion of CBT homework assignments (Carney, Freedland et al., 2016). Carney,
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Freedland et al. (2016) concluded that patients who were under severe stress were less
responsive to treatment for depression. This study was significant, as it also showed
success with CBT treatment. Furthermore, it gave insight on why patients might be less
responsive to treatment, and clinicians should take note of this before commencing with
treatment of MDD patients (Carney, Freedland et al., 2016).
Dodda et al. (2014) aimed to examine the gradient boosted model (GBM). The
GBM is a statistical technique that can identify and measure variables that influence
treatment outcomes when it is applied to clinical trial data. Dodda et al. applied the GBM
to 12 clinical trials, totaling 4987 human subjects. The subjects included in the trial had
been diagnosed with an acute depressive episode, and they had been treated with
duloxetine, an SSRI, or placebo to predict treatment remission. After the GBM had been
applied, significant differences could be measured regarding treatments and which
variables associated with remission. Dodda et al. concluded that the GBM provided
greater flexibility regarding the identification of patient variables that predicted
remission, and it might give insight to individualized treatment options. The information
gained from this study furthered the argument on the mystery of the various treatments
available for MMD and the various treatment outcomes that were experienced by
individuals (Dodda et al., 2014).
Rush et al. (2012) postulated that MDD was often chronic, recurring, or both. The
researchers sought to determine whether MDD was chronic, recurring, or both and
whether it correlated with long-term treatment outcomes. Their cohort study included
patients across all ages who were diagnosed with MDD. The treatment groups included
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389 chronic and recurring MDD patients, 257 chronic non-recurring MDD patients, 1614
non-chronic recurring MDD patients, and 387 non-chronic and non-recurring MDD
patients. The aim was for the patients to remit or at least improve after 14 weeks of
citalopram treatment, including follow-up treatment for 12 months. In addition, 85% of
participants were administered a chronic or recurrent course and 15% had both. Chronic
MDD had a correlation with increased sociodemographic disadvantage. Recurrent MDD
correlated with earlier age diagnosis and genetic history of depression, as well as
substance abuse. Chronic MDD associated with slow response to treatment and low
remission rates. Higher risk of relapse associated with the chronic and recurring MDD
treatment group. Rush et al. determined that chronic recurring MDD might be predictors
of long-term MDD treatment outcomes. Rush et al. showed the severity for the need of
more research regarding treatment outcomes to ensure remission for all patients.
Treatment Resistant Depression
Remission status is not a guarantee, as several MDD patients have proven to be
unaffected by several treatments, and successful treatment does not necessarily result in
remission. For example, Gaynes et al. (2009) sought to determine which treatments
proved most effective for patients diagnosed with MDD who have proven to be
unaffected by treatment, or whose symptoms did not go into remission through a largescale practical clinical trial. Participants were recruited from psychiatric and primary care
clinics. After recruitment, participants began on citalopram. Clinic physicians followed
an algorithm-guided acute-phase treatment through five visits over 12 weeks with the
patients. Patients whose depression had still not remitted after each sequence were
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eligible for further trials. They concluded that none of the medication administered had a
significant effect on the patients (Gaynes et al., 2009). It was clear that several steps
would be needed for patients to go into remission successfully, as the remission rates
were even lower than expected for the trial. Remission also became a less likely outcome
after two vigorous trials, and even more complicated medication regiments would be
needed to successfully achieve remission (Gaynes et al., 2009). The evidence of more
complicated treatments was minimal. This study proved the need for even more research
and clinical trials to make discoveries on the treatment of MDD.
Successful treatment administration. Regarding successful treatment
administration, some researchers have suggested predictive analytic models. Kessler et al.
(2016) posited that data predictive analytic models might be more helpful to assist
physicians in making decisions on treatment when compared to the lack of information of
biomarkers as predictors of treatment outcome. Kessler et al. investigated the validity of
prediction based on symptoms and clinical features that can be easily assessed. Kessler et
al. looked at existing research to determine the validity of these factors to predict
treatment outcomes to assist in individualized treatments. Kessler et al. further expressed
the need of protocol that could collect data over time to determine the predictors of the
heterogeneity of MDD and the response of patients to treatment. The data collected
should be used to focus on the treatment response of patient populations, which remained
a mystery (Kessler et al., 2016).
According to McGrath et al. (2013), less than 40% of patients who have been
diagnosed with MDD and have received initial treatment, achieved remission. McGrath
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et al. posited that the identification of a biomarker that could predict treatment outcomes
would make a considerable impact on health care. The brain glucose metabolism of 65
patients (male and female, ages 18-60 years with untreated MDD) was measured at
baseline, and the patients were treated with escitalopram oxalate or cognitive behavior
therapy over 12 weeks. Remission was measured through HDRS. Patients who were not
in remission after the first 12 weeks were opted for treatment for another 12 weeks, with
treatment including escitalopram, as well as cognitive behavior therapy (McGrath et al..
2013). From 65 patients, 38 showed the following clear results: 12 patients who achieved
remission through cognitive behavior therapy and nine nonresponders, as well as 11
patients who achieved remission through escitalopram and six nonresponders (McGrath
et al.. 2013). The researchers concluded that the insula metabolism-based treatmentspecific biomarker was identified in this study, and it might provide the first objective
marker to assist in treatment selection for patients with MDD (McGrath et al., 2013).
Increasing the chance of successful treatment. Aside from the fact that accurate
predictive variables have not been found to determine treatment outcomes before
treatments are administered, alternative methods to increase the chances of successful
treatment have been researched. Fava et al. (2015) conducted a randomized, double blind,
and placebo-controlled trial to investigate the efficacy of CP-601,927. CP-601,927 is an
amplifying agent of antidepressant drugs in patients with MDD that has insufficient
response to selective serotonin reuptake inhibitors (SSRIs). Fava et al. did not find a
significant difference in the relief of depression from baseline to Week 14 when the CP610,927 treatment was compared to placebo. Fava et al. further found an association
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between increased BMI and specific biomarkers, which suggested that baseline leptin,
affected treatment outcome significantly. Fava et al. concluded that CP-601,927 was not
an enhancer of antidepressants, as no difference was observed when compared to placebo
in MDD patient that had an insufficient response to SSRIs.
Jani et al. (2015) provided valuable insight with their review on the literature
regarding biomarkers and the ability to predict depression severity, treatment response
and remission status, as well as the occurrence of other illnesses. Jani et al. postulated
that the diagnosis of depressive symptoms was difficult to establish in primary care, as
that was where the majority of depression patients were being cared for. Jani et al. stated
that comorbidity was the cause. Many studies have included biological pathways in their
studies on the treatment of MDD, and yet there has not been conclusive evidence on
accurate predictive biomarkers (Jani et al., 2015).
Patients with heart failure with comorbid depression who could achieve remission
proved to have greater improvement in social function, physical function, and quality of
life (Xiong et al., 2012). It could thus be concluded that more studies were definitely
needed to increase the chances of remission. There were variable factors influencing
chances of remission (initial vigorous ineffective treatment, previous substance abuse,
late diagnoses), and more research was needed to determine the biomarkers responsible
for this phenomenon (Xiong et al., 2012). Physicians should also take greater care before
administering a specific course of treatment, as the extent of several treatments and drugs
could result in a patient becoming treatment resistant (Xiong et al., 2012).
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Inflammatory Biomarkers and Treatment Responses Mediated by Age, Race, and
Gender
Wolitzky-Taylor et al. (2012) posited that it was of utmost importance to
understand what circumstances, as well as for whom, biological composition treatments
were most effective. Wolitzky-Taylor et al. found that there was a correlation between
poorer response to treatment and higher measures of neuroticism at baseline.
Comorbidity, race, gender, age, or severity of the disorder was not found predictive of
treatment outcomes (Wolitzky-Taylor et al., 2012). In this section, I look at the current
literature in the light of age, race, and gender as mediators of treatment response.
Age. Further proof of the association of depression and its correlation with
inflammatory biomarkers has derived from suicide victims. In an investigation of
adolescent suicide victims, higher levels of IL-1β, IL-6, and TNF-α were measured in
comparison to normal controls, further aiding the correlation between inflammatory
biomarkers and depression (Miller & Raison, 2016; Walker et al., 2014). Higher levels of
inflammatory cytokines (TNF-α, IL-1β, IL-6, and IFN-γ) were discovered in pediatric
patients experiencing first-episode psychosis (Walker et al., 2014). However, this age
specific evidence did not prove that age was a mediator, but merely furthered the premise
of a correlation between MDD and inflammatory biomarkers.
As stated previously, depression is often found as comorbidity in patients with
other inflammatory illnesses. There is also inflammatory treatment for illnesses, which
may result in depressive symptoms in the patients receiving the therapy. Hauser et al.
(2002) concluded that Interferon (IFN) therapy associated with the development of MDD
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in patients with hepatitis C (HCV). Hauser et al. sought to determine whether IFNinduced MDD could be treated effectively with open-label antidepressants (selective
serotonin reuptake inhibitors/SSRIs). Hauser et al. also examined, among others, the
mediation of age and gender. Thirteen out of 39 HCV patients on IFN therapy became
depressed and were treated with citalopram, a SSRI antidepressant. Variables, such as
age, gender, past history of MDD, or substance use, did not mediate the outcome. There
were significantly lower numbers of African American patients who had become
depressed. It took an average of 12.1 weeks for patients to develop MDD from IFN
therapy. Eleven of the depressed patients responded positively to the treatment
administered. Hauser et al. concluded that MMD was a common risk factor for HVC
patients who were being treated with IFN therapy. Doctors should be alert for the
manifestation of MDD in their HVC patients. Citalopram proved an effective treatment
for IFN-induced MDD patients (Hauser et al., 2002).
Depression is known to affect population groups of various ages, and yet the
research on treatments available and treatment outcomes for children and adolescents
remains limited. Luby (2013) posited that there was evidence of depressive disorders and
anxiety in children as young as 3 years of age. The development of age appropriate
treatment is lagging behind. After comprehensive research, the consensus was that
adapted forms of cognitive-behavioral therapy had been successful in a small randomized
controlled environment (Luby, 2013). The adaptive form of cognitive-behavioral therapy
included the involvement of primary caregivers, as well as cartoon-based material.
Furthermore, adapted forms of Parent Child Interaction Therapy also appear promising
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for the improvement of child depression and anxiety. Direct treatment of the youngest
children within a family seems to be necessary for a long-term effect (Luby, 2013). This
study provided insight to the available therapies for preschool children diagnosed with
anxiety and depression. This added to the premise of the current study: Age might be a
mediator of therapy outcomes for the treatment of depression.
Allison, Nativio, Mitchell, Ren, and Yuhasz (2014) commented on the lack of
knowledge in the detection of depression in children who are still in school. The benefit
of early detection of mood disorders in children is prompt treatment. Mood disorders
affect children’s’ schoolwork, and the disease may worsen if not detected timeously
(Allison et al., 2014).
Cipriani et al. (2016) agreed with Allison et al. (2014) and Luby (2013). They
posited that MDD was one of the most common mental disorders, but it was yet to be
determined which antidepressant and/or treatment was most effective. Cipriani et al.
focused on 34 trials, 5260 participants (children and adolescents) and 14 antidepressant
treatments. After research, Cipriani et al. decided that trials of amitriptyline, citalopram,
clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine,
mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine would be
included. Trials that included treatment-resistant patients, treatment duration of less than
4 weeks, or a sample size of less than 10 patients were excluded (Cipriani et al., 2016).
The results of the data analyses showed that only fluoxetine was statistically more
effective than placebo for treatment efficacy (Cipriani et al., 2016). Fluoxetine proved
more tolerable compared to duloxetine and imipramine. Discontinuations, because of side
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effects, happened more often for imipramine, venlafaxine, and duloxetine when
compared to placebo. The conclusion was that none of the drugs seemed extremely
effective, although fluoxetine proved the best choice compared to the other
antidepressants (Cipriani et al., 2016). The results of the study showed the ineffectiveness
of drugs being administered to children and adolescents, and proved that there was a lack
of information on treatments for children and adolescents diagnosed with MDD (Cipriani
et al., 2016).
Mills, Scott, Wray, Cohen-Woods, and Baune (2013) postulated that the
relationship between depression and cytokines in adults was evident, but that the research
was lacking on this relationship for adolescents. Mills et al. reviewed the available
literature on the relationship between cytokines and depression in adolescents and
investigated how cytokines related to adolescent depression concerning neurobiological
theories of depression. After extensive research, 18 studies were chosen, which had
measured depression and cytokines in adolescents (Mills et al., 2013). The analyses of the
studies showed that adolescents diagnosed with depression expressed age-specific
characteristics of the immune and inflammatory system, more specifically, NK cell
activity and proinflammatory cytokines. Mills et al. (2013) concluded that
neurodevelopment, hormones, stress, and trauma influenced the role of cytokines in
adolescents with depression. Neurobiological differences might exist between adolescent
MDD and adult MDD. This aided the hypothesis of the study at hand that age might be a
mediating factor in the treatment of MDD. Mills et al. stated that more information on
this subject could lead to better treatment of MDD for adolescents.
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Several studies have been conducted on the treatment responses of adults to
various treatments of MDD. Few studies, up to this point, have been devoted to
determining the correlation between age and the treatment outcomes of the treatment
available. Brent et al. (1998) sought to determine the predictors of treatment outcomes
across several different treatments, and the predictors associated with the different
responses to treatment in adolescents. Brent et al. included a sample of 107 subjects (13
to 18 years old) who have been diagnosed with major depression. The subjects were
assigned 1 of 3 different psychosocial treatments (12 to 16 sessions). The treatments
included cognitive-behavioral therapy (CBT), systemic-behavioral family therapy, or
nondirective supportive therapy. The results showed that clinical referral, as opposed to
subjects responding to advertisements, predicted continued depression, and were
mediated by hopelessness (Brent et al., 1998). Comorbid anxiety disorder, higher levels
of cognitive distortion and hopelessness were also determined as predictors of depression.
Clinical remission had a positive correlation with self-reported depression. Differential
treatment efficacy was predicted by comorbid anxiety and maternal depressive symptoms
(Brent et al., 1998). CBT was more effective when compared to the other therapies used,
even with the mentioned predictors present. Brent et al.’s (1998) study was significant to
the study at hand, as it provided insight on the results of different therapies, and which of
the therapies would likely be the best option for difficult-to-treat patients.
A lack of significant research on the effects of depression on the elderly was also
determined. As stated previously, depression does not discriminate based on age. A
cross-sectional study conducted in Stockholm, Sweden aimed to determine the
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prevalence of depression in patients over the age of 60 without dementia (Karlsson,
Johnell, Sigström, Sjöberg, & Fratiglioni, 2016). Karlsson et al. (2016) found that the
prevalence of depression was 5.9%. Moreover, 8.3% of the sample was prescribed as an
antidepressant, and 0.9% was treated with psychotherapy. Karlsson et al. concluded that
depression in old age often remained untreated, as patients were not diagnosed at all or
were even misdiagnosed. As a result, these patients often received inappropriate
treatment (Karlsson et al., 2016). The study did not include age as a mediator for
depression treatment, although it did provide information on the lack of depression
treatment for elderly individuals with MDD.
Using age as a predictor of treatment outcomes in the administration of MDD
treatment has not been proven definitively. Maes, Mihaylova et al. (2012) posited that
MDD associated with cell-mediated immunity (CMI), increased neopterin levels, and
higher levels of proinflammatory cytokines (PICs). They speculated that PICs might
cause depressive, melancholic, and chronic fatigue (CF) symptoms. In addition, 85 MDD
patients and 26 normal controls were used for the study. The serum levels of these
patients were measured, and their severity of depression was measured with the Hamilton
Depression Rating Scale (HDRS) and severity of CF with the Fibromyalgia and Chronic
Fatigue Syndrome (FF) Rating Scale (Maes, Kubera et al., 2012). A positive relationship
was evident between neopterin, the PICs, and amount of depressive episodes. Neopterin
and TNFα were correlated with melancholia and CF. Melancholia was predicted by the
HDRS and neopterin. CF was predicted by age, the FF score, and TNFα (Maes, Kubera et
al., 2012). Inflammatory responses may be accompanied by the onset of depression, as
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well as depression symptoms. Previous depressive episodes could enhance PIC responses
and increase the risk of new depressive episodes. Inflammation could cause the
reoccurrence of depression (Maes, Kubera et al., 2012). The results of this study showed
further proof of the effect that inflammatory biomarkers have on depression (Maes,
Kubera et al., 2012). It also showed merit for the hypothesis of this study that treatment
responses might be mediated by age.
From another perspective, of the preventative nature, early detection of depression
may result in treatment that is more effective and a higher chance of remission.
Khandaker, Pearson, Zammit, Lewis, and Jones (2014) aimed to determine whether high
levels of inflammatory biomarkers in children were predictors of mood disorders later in
life. Their study involved 4500 individuals aged 9 years. The serum levels of the
participants were measured at Age 9, and again at 18. The Clinical Interview Schedule–
Revised (CIS-R) and Mood and Feelings Questionnaire (MFQ) were used to evaluate the
participants. The results showed a significant higher risk for the children with high
baseline inflammatory biomarkers to have depression at the age of 18. Khandaker et al.
(2014) also found that higher levels of IL-6 levels at baseline could results in psychotic
disorder at Age 18. The researchers concluded that inflammatory biomarkers might
improve current methods of intervention and even provide preventative measures.
Khandaker et al. also accumulated the high likelihood of comorbidity between heart
disease, diabetes mellitus, depression, and schizophrenia to inflammatory biomarkers.
In relation to the above mentioned study, a lack of diagnosis, and as a result
treatment, would result in a higher percentage of fatalities. Czyz, Horwitz, Eisenberg,
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Kramer, and King (2013) posited the challenge of personal barriers that prevented
suicidal adolescents from seeking help from professionals. Czyz et al. sought to
determine the demographical and clinical variables that might influence the
abovementioned challenge. The 165 participants were found via a web-based treatment
linkage intervention questionnaire. The barriers identified were the perception of the
students that they do not need treatment (66%), lack of time (26.8%), and preference for
self-management (18%). Stigma was mentioned by only 12% of students (Czyz et al.,
2013). Efforts to promote professional help to suicide risks should be aimed at removing
these barriers to be successful.
Most of the studies reviewed were only concerned with the lack of identification
in late life depression, as well as the lack of early detection, the lack of treatment
available for preschool children, and the increased levels of inflammatory biomarkers in
suicidal adolescents, and yet few of the studies specifically investigated age as a mediator
(Allison et al., 2014; Wallace et al., 2012). The studies on age as a mediator for
depression and treatment outcomes remain inconclusive. More studies are needed to look
at this specific variable; although, that may be increasingly difficult with the amount of
treatments available and the lack of response prediction (Damián, Pastor-Barriuso,
Valderrama-Gama, & de Pedro-Cuesta, 2016).
Race. As discussed previously, Hauser et al. (2002) determined that variables,
such as age, gender, history of MDD, or substance use, did not mediate the outcome, but
that significantly lower numbers existed of African American patients who had become
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depressed. The research on race as a mediator of treatment outcomes is extremely
limited. In this section, I examine the outcomes of the research obtained on this matter.
Any predictors of treatment outcomes that may be related to race may assist
health care providers to administer the correct treatment for MDD from the first
diagnoses. Adamsa et al. (2014) sought to determine the differences in the process of
clinical depression of African American and African-Caribbean patients in comparison
with White patients in the United States and England. The researchers investigated racial
disparities that might affect depression treatment. Moreover, 108 doctors were included
in the study and were asked to describe their thought processes after viewing videorecorded simulated patients with identical symptoms of depression. Adamsa et al. made
use of the CliniClass system to analyze the data. This system provides the capturing of
information about microcomponents of clinical decision-making and assists in the
detailed analysis of diagnostic, intervention and management decisions of doctors. Actors
portrayed the several different races, as well as male and female patients in these
recordings. The doctors were randomly selected stratified by country (United States vs.
England), gender, and years of clinical experience (less vs. very experienced). The
findings did not show significant bias among the races under study, except for the
outcomes expected and the treatments available for African Americans in comparison
with White American patients in the United States (Adamsa et al., 2014). Adamsa et al.
(2014) concluded that great clinical uncertainty existed in diagnosing depression amongst
Black patients in comparison with White patients in England. The evidence suggested
that more attention was paid to Black patients physical rather than psychological ailments
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to reach diagnosis in both countries. This implied that doctors in both countries have a
less well developed mental model of depression for Black compared with White patients
(Adamsa et al., 2014).
When administering antidepressant treatment, bias might play a role for some
health care providers. Pickett, Greenberg, Bazelais, and Bruce (2014) sought to determine
if race or ethnicity influences the treatment of depression with the use of cross-sectional
analyses of administrative data. The study was conducted in a healthcare facility in New
York, and the participants included 3744 patients over the age of 65 who had been
diagnosed with depression. The severity of depression in these patients was measured via
the Measurements Patient Health Questionnaire. All other data used for the study were
obtained from the patient electronic medical record. The results showed that 6.52% of the
patients included in the study diagnosed positive for depression, 11.11% screened
positive for depression with the use of the questionnaire, and 13.39% were prescribed
with antidepressant drugs (Pickett et al., 2014). The chances of an antidepressant
prescription among those who screened positive for depression were 0.42 for African
Americans and 0.49 for Hispanics in comparison with Caucasians. The findings
suggested that there remained discrepancies among depression treatment for elderly
patients across races, with Caucasians being favored (Pickett et al., 2014).
In terms of treatment response across races, little information was available, as
few studies investigated the probability thereof. Murphy et al. (2013) conducted one such
study, and they concluded that Black participants had a worse response to antidepressant
treatment when compared to White participants. The discrepancies remained evident,
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even after socioeconomic and initial clinical factors were accounted for in the study.
According to Murphy et al., some researchers contributed these discrepancies to genetics,
but none have determined the reason for these discrepancies. Murphy et al. used genomewide single-nucleotide polymorphism (SNP) data to examine the independent
characteristics of race and genetics. Murphy et al. conducted secondary data analyses that
included 1877 patients who were treated with citalopram over the course of 10 weeks.
From the 1877 sample size, 1464 participants were White, 299 were Black, and 114 were
other or mixed race. The researchers made use of structural equation modeling to
examine the direct and indirect influences of and possible predictors of response to
treatment and change was observed using the Quick Inventory of Depressive
Symptomatology (QIDS) score (Murphy et al., 2014). The severity of depression was
measured at baseline and after 10 weeks of treatment. The results showed a significant
effect of socioeconomic factors, clinical factors, race, and anxiety on the response to
treatment (Murphy et al., 2014). These factors were found as predictors of the treatment
response of patients. In contradiction, no direct effects of genetic ancestry were found.
Genetic African ancestry predicted poorer treatment response in all models. Genetic
ancestry, rather than self-reported race, provided significant information on the residual
differences. The findings emphasizes the need for more clinical trials, especially ones
including more African-American patients (Murphy et al., 2014).
The available studies on depression treatment across various races were
particularly limited, and more research investigating race as a variable would add to the
literature. Only a few sources had observed poorer response to treatment in Black
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patients. The above studies did not necessarily attempt to determine race as a variable for
the effectiveness of depression treatment, but rather stated the lack of or differential
treatment across races.
Gender. Miller and Raison (2016) posited that depression in women increased
significantly when compared to men. This phenomenon was even more significant during
the reproductive years. Recent studies have shown women to be more prone to the effects
of inflammation on behavior, which resulted in more significant symptoms of depression.
Women are also believed to be at higher risk for depression induced by doses of
interferon-α (IFNα). Being prone to depressive symptoms caused by inflammation, these
symptoms might have provided women with more protection to fight infection and heal
wounds as well as avoiding illness. Inflammation could have negative effects on
reproduction, as it reduced fertility and impaired lactation. This could provide
explanation as to the higher increase in depression in women when compared to men, and
yet it might have helped women to cope with and avoid pathogens and the inflammation
related to them with depression being the price they pay (Miller & Raison, 2016).
In agreement with Miller and Raison (2016), the following study also found that
women were more prone to the onset of depression. Bengtson et al. (2016) conducted a
study to determine the discrepancies of depression treatment effectiveness across HIVinfected patients from different genders and races. 31,000 HIV-infected adults were
included in the study and were obtained from eight different clinics where they have been
diagnosed with depressive symptoms within 1 month of HIV diagnoses. Bengtson et al.
(2016) measured the depressive symptoms of the patients using the Patient Health
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Questionnaire-9 (PHQ-9). Antidepressant treatment was defined as a patient having a
current antidepressant prescription. Evidence-based antidepressant treatment was
considered if treatment changes had been observed from a person’s most recent PHQ-9,
in accordance with clinical guidelines. Bengtson et al. used multivariable Cox
proportional hazards models to determine correlations between gender, race, and the
depression outcomes. Bengtson et al. determined that 47% of the sample showed an
indication for antidepressant treatment. Bengtson et al. study found significant drop-offs
along the depression treatment cascade. The results showed definite discrepancies across
all variables. Women were found as more prone to show the need for antidepressant
treatment, receive antidepressant treatment, and receive evidence-based antidepressant
treatment, even after accounting for race. Blacks, Hispanics, and other races were less
likely to seek antidepressant treatment, in comparison to White patients (Bengtson et al.,
2016).
Dementia, an inflammatory illness, has also been found correlated with
depression, especially in elderly patients, as they are more often associated with
dementia. Matsushima et al. (2015) posited that the risk of depression in dementia
patients was rising, and inflammation presented in both illnesses might be the reason. The
researchers conducted a study on 64 patients over the age of 65 who have not been
diagnosed with dementia and who were not living in any healthcare facility. The
inflammation levels of interleukins (IL)-1β, IL-2, IL-6, soluble interleukin-2 receptor
(sIL-2R), soluble interleukin-6 receptor (sIL-6R), high sensitivity C-reactive protein
(hsCRP), and tumor necrosis factor (TNF)-α of the patients were measured at baseline, as
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well as after 3 years. The severity of depression was measured using the Beck Depression
Inventory (BDI) and cognitive decline for dementia was measured with the Mini-Mental
State Examination (MMSE), Frontal Assessment Battery (FAB), and Clock Drawing Test
(CDT), also at baseline and follow-up. The analyses were deemed appropriate across all
ages, genders, and educational levels (Matsushima et al., 2015).
The results of the cross-sectional analysis, proved soluble IL-2 receptor (sIL-2R)
associated only with men, according to the MMSE score at baseline (Matsushima et al.,
2015). The longitudinal analysis, however, showed none of the inflammatory biomarkers
correlated with depressive symptoms or cognitive decline. The findings showed that sIL2R associated with current cognitive function in men, yet none of the inflammatory
biomarkers predicted future depressive state or cognitive decline in the communitydwelling healthy older sample (Matsushima et al., 2015). The results of this study showed
no evidence of gender as a mediator in depression treatment (as treatment was not part of
the study), and yet also disagreed with the hypothesis of inflammatory biomarkers being
a predictor in mental illnesses (Matsushima et al., 2015).
Cardoso et al. (2014) postulated on recent studies that had evaluated the role of
brain-derived neurotrophic factor (BDNF) in mood disorders. Cardoso et al. sought to
determine the differences of serum neurotrophic factors (BDNF, NGF, and GDNF) in
patients diagnosed with depression and normal controls. Cardoso et al. also stratified the
results according to gender in a sample of young patients aged between 18 and 29. The
design of their study was cross-sectional. They used the ELISA method to measure the
concentrations of neurotrophic factors. The severity of and length of depression was
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determined by the Structured Clinical Interview and the 17-item Hamilton Rating Scale
for Depression (HRSD). The levels of BDNF and GDNF measured were found to be
lower in major depressive disorder (MDD) patients compared to controls. The levels of
NGF measured were higher in MDD patients versus controls. BDNF was correlated with
the duration of disease only in women. NGF was associated with the severity of
depressive symptoms, anxiety and disease duration in women in comparison to men, but
was also correlated with disease duration in men (Cardoso et al., 2014). The finding
showed that significant neurochemical differences in NGF and BDNF correlated with the
clinical features of MDD when patients were stratified by gender (Cardoso et al., 2014).
The research shows that treatment efficacy is not significantly mediated by age, or
race, but that variables, such as self-concept, perspective of wellbeing, and selfawareness, may be more likely to mediate treatment outcomes and remission. However,
some of the studies did suggest that Blacks were less likely to have a positive response to
depression treatment, and other studies also showed evidence that women are more prone
to the manifestation of depression. It can, however, still be concluded that the outcomes
of treatment is very difficult to predict, with so many variables at play. More studies are
needed to gain concrete knowledge on the subject.
Summary and Conclusions
Current interventional pharmaceutical therapies targeted for depression are not
considered adequate enough to achieve sufficient remission following treatment
(Hashimoto, 2015; Slavich & Irwin, 2014; Wray et al., 2012). Depression yields a notable
burden in terms of adverse symptomatology, decreased productivity, increased morbidity,
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and also contributes to rising mortality as a result of suicide (Wray et al., 2012).
Depression is one of the most significant health challenges worldwide, and is one of the
biggest contributors of health disability and costs. It has been profusely stipulated that
depression is heterogeneous, and current diagnostic measures rely on symptoms which
has been found to be unreliable and inconsistent (Jani et al., 2015). Incorporating
inflammatory biomarkers in the diagnoses and selecting of treatment for psychiatric
diseases would make an immense difference in a field that mainly relied on interviews
and questionnaires of patients for evaluation (Lopresti et al., 2014).
There are resources providing evidence of the relationship between inflammatory
biomarkers and depression, yet there remains a lot to be discovered regarding the effects
of biomarkers on treatment efficacy. Depression remains a heterogeneous disease.
Specific biomarkers and the extent of their influence on treatment responses and
remission outcomes are yet to be determined, as well as whether a definite mediation is
found from variables such as age, race and gender. There is less research showing the
effect of inflammatory biomarkers in adolescence, while the effect of inflammatory
biomarkers is believed to happen at key stages in a patient’s life, such as adolescence.
The literature shows evidence of higher levels of TNF-α, IL-6, and IL-10 in patients
during the early phases of bipolar disorder, where CRP has been found to predict the risk
of depression (Walker et al., 2014). The literature also showed possibilities for alternative
treatment that should be explored further. The efficacy of antiinflammatory drugs has
proved successful in several studies (Fond et al., 2013; Rapaport et al., 2016; Sua, 2012)
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When patients are diagnosed with depression, it is expected that the process to
remission is lengthy, including several types of treatment including antidepressant drugs
and therapy, and yet remission remains not guaranteed. Fava and Rush (2006) posited
that most patients diagnosed with MDD never reached remission. The severity of
depression in these patients are often much worse compared to patients who are found to
remit. Often, several treatments and antidepressant drugs are administered to these
patients to find an appropriate and effective treatment to reduce the symptoms in the
least, with remission as a long-term goal.
The current study might provide valuable insight into the relationship between
biomarkers and treatment efficacy, thereby improving treatment options and outcomes
(Lopresti et al., 2014; Strawbridge et al., 2015). More evidence on inflammatory
biomarkers and the relationship with various illnesses would provide great insight for
individualized treatment, resulting in a lower rate of patients becoming treatment
resistant, greater remission possibilities, and a reduction in the mortality rate across
populations. Chapter 3 contains the methodology involved in this quantitative secondary
analysis study.
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Chapter 3: Research Method
The purpose of this quantitative, secondary data analysis was to determine if there
was a relationship between inflammatory biomarkers and treatment efficacy in persons
diagnosed with depression who demonstrated a previous lack of remission. In this
chapter, I expound on the research methodology and design that was introduced in
Chapter 1. The chapter includes details relating to the study methodology, the data
analysis plan, and threats to the validity of the study. The chapter concludes with a
summary.
Problem Statement
Current interventional pharmaceutical therapies targeted for depression are not
considered adequate enough to achieve sufficient remission following treatment
(Hashimoto, 2015; Slavich & Irwin, 2014; Wray et al., 2012). Depression yields a
adverse symptomatology, decreased productivity, and increases in morbidity (Wray et al.,
2012). Moreover, depression also contributes to the facilitation of rising mortality as a
result of suicide (Wray et al., 2012). In clinical trial data on outcomes in depression,
scholars have demonstrated that achievement of remission is decreasing (Gartlehner et
al., 2016; Gaynes et al., 2009; Steidtmann et al., 2013). There is a need to implement
strategies that adequately stratify subpopulations to determine among which groups
remission rates are decreasing and to examine how remission outcomes can be
successfully met for these groups (Gaynes et al., 2009; Lopresti et al., 2014). I researched
the relationship between inflammatory biomarkers and treatment efficacy for depression.
These inflammatory biomarkers respond to the psychosocial stressors associated with
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depression, and these both precede and follow diagnosis with major depressive disorder
(Miller & Raison, 2016).
Research Design and Rationale
For this study, I employed a quantitative secondary data analysis from an existing
dataset from a sponsored experimental, randomized, double-blind, placebo-controlled,
and IRB-approved clinical trial (ClinicalTrials.gov Identifier: NCT01098240). I focused
on the comparison of an add-on novel pharmacotherapy and placebo in a population
diagnosed with depression who demonstrated a previous lack of remission. The
independent variables for this study included inflammatory biomarkers: adiponectin, hsCRP, leptin, IL1-β, IL6, and TNFα. The dependent variable was the remission outcome,
as measured by the MADRS. Mediating variables included age, race, and gender (see
Table 1).
In the original study, Fava et al. (2015) failed to achieve efficacy of the novel
pharmacotherapy, as compared to the placebo in the augmentation of antidepressant
therapy (ADT) in patients with MDD, as measured by the MADRS. The sample selected
for their study included a mixed MDD population, and participants were not stratified
according to inflammatory biomarker status (Fava et al., 2015). Nicotinic agonists were
more efficient compared to acetylcholine at inhibiting the inflammatory signaling and the
production of proinflammatory cytokines (Cai, Deitch, & Ulloa, 2010; Jonge & Ulloa,
2007). This nicotinic antiinflammatory pathway might have clinical implications, as
treatment with nicotinic agonists could modulate the production of proinflammatory
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cytokines from immune cells. Therefore, this study might help to support these
conclusions by examining outcomes based on inflammatory biomarkers.
A correlational research design was selected for this study to address the research
questions relating to the association or relationships between variables. By using a
correlational research design, I could determine the extent of relationship between two or
more variables using statistical data. Based on an analysis of relationships using a
correlational research design, the researcher can identify whether changes in certain
variables are associated with changes in other variables, along with the direction, degree,
magnitude, and strength of those associations (Burns & Grove, 2005; McLeod, 2008;
Walker, 2005). Correlation does not necessarily imply causation (McLeod, 2008);
therefore, no causal relationships were identified in this study.
A correlational quantitative research design was appropriate for this study and
was consistent with the research designs needed to advance knowledge in this field. The
secondary data set used for this study contained numbers, which were analyzed
quantitatively. Additionally, other researchers in this field who have conducted studies
relating to inflammatory markers have used similar research designs (Brenner et al.,
2014). Empirical research related to the measurement of cytokines was emergent and
limited (Brenner et al., 2014); therefore, research designs, such as this, could add to the
body of literature relating to these inflammatory biomarkers.
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Table 1
Independent, Dependent, and Mediating Variables
Independent Variables

Dependent Variable

Mediating Variables

-adiponectin

-depression remission

-age

-C-Reactive Protein (hs-

outcome

-race

CRP)

-gender

-leptin
-interleukin 1-β (IL1-β)
-interleukin 6 (IL6)
-tumor necrosis factor-α
(TNFα)

Methodology
I used existing datasets from a sponsored experimental, randomized, double-blind,
placebo-controlled, and IRB-approved clinical trial (ClinicalTrials.gov Identifier:
NCT01098240). The data sets were retrieved from the sponsor pharmaceutical company,
Pfizer Inc., and transferred to SPSS for analysis. To answer the research questions, an
analysis of variance and a linear regression analysis was conducted.
Archival Data
The archival data used for this study were from a clinical study conducted by
Pfizer, Inc. between June 2010 and September 2011. The study was an experimental,
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randomized, double-blind, placebo-controlled, and IRB-approved clinical trial entitled A
Study of the Efficacy and Safety of CP-601,927 Augmentation of Antidepressant
Therapy in Major Depression (ClinicalTrials.gov, 2013). The study was identified in a
registry housed by ClinicalTrials.gov, which maintained a database of publicly and
privately conducted studies in the United States and internationally. The database
provided information relating to studies contained in the registry, including the study
protocol, the purpose of the study, recruitment status, and the eligibility criteria for
participants. The trial selected for this study also included results from the trial as a part
of the database registry. To obtain the data set used for this study, I requested permission
directly from Pfizer, Inc. To do so, I contacted the Pfizer ClinicalTrials.gov Call Center
by phone and via e-mail. A formal written request for the data and permission to use the
data for this study were submitted and approved.
Population and Sample
There were 297 participants included in the study. Eligible participants included
men and women between the ages of 18 and 65 years. To be included, participants had to
have been diagnosed with MDD without psychotic features, with the duration of the
current episode of MDD being at least 8 weeks prior to enrollment in the study.
Participants were required to receive ongoing treatment using ADT at the time of
screening, including escitalopram, citalopram, fluoxetine, paroxetine controlled-release,
and sertraline. Otherwise, the participants had to be medically healthy
(ClinicalTrials.gov, 2013).
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Instrumentation and Operationalization of Constructs
Another instrument used in this study was the MADRS (Montgomery & Asberg,
1979). The MADRS was used by researchers to measure the severity of depressive
symptoms in patients. Due to its extensive use, there have been many researchers who
validated its use in the assessment of depressive symptoms. For example, Duerte-Guerra
et al. (2016) conducted a study to validate the use of the MADRS to assess the depressive
symptoms of bariatric surgery candidates. Using a sample of 374 obese patients, DuerteGuerra et al. compared results from the MADRS to results from the Structured Clinical
Interview for DSM-IV Axis I Disorder (SCID-I). Based on the data of the study, DuerteGuerra et al. concluded that the MADRS was a reliable and valid assessment tool for
depressive symptoms.
Similarly, Kjærgaard, Arfwedson Wang, Waterloo, and Jorde (2014) tested the
reliability and validity of several instruments for measuring depressive symptoms,
including the MADRS. In their study, healthy participants were interviewed using the
MADRS. The SCID-CV was used to diagnose a major depressive episode in the healthy
participants and as a result, 6% of the participants were diagnosed as experiencing a
MDE. The instruments in question were found to be internally consistent and in
alignment with the SCID-CV. Kjærgaard et al. concluded that the MADRS, along with
the other instruments, were appropriate screening instruments for identifying MDE in
healthy populations.
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Data Analysis Plan
Based on the immune-cytokine POD and lack of research on inflammatory
biomarkers in mental health, I included the following research questions and associated
hypothesis:
RQ1: Is there any relationship between inflammatory biomarkers, including
adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα and treatment efficacy in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H1o: There is no relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
H1a: There is a relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
RQ2: Is there any relationship between remission outcomes, as measured by
MADRS uniform, for each inflammatory biomarker in persons diagnosed with
depression who have demonstrated a previous lack of remission, as measured by the
MADRS?
H2o: There are no relationships between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
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H2a: There is a relationship between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
RQ3: Is there any relationship between treatment response, as measured by the
MADRS, and inflammatory biomarkers mediated through age, race, or gender in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H3o: There is no relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
H3a: There is a relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
The data from the clinical trial were transferred to SPSS for analysis. The data
were analyzed for any missing data and adjusted accordingly to determine the number of
valid data entries that could be included in the research. Missing data were coded as
missing in the SPSS worksheet, and participants with missing data were removed from
the data set and were not included in the analysis. A one-way ANOVA was conducted to
address RQ1 to determine if there was a difference between inflammatory biomarkers
and treatment efficacy in persons diagnosed with depression who demonstrated a
previous lack of remission, as measured by the MADRS. I verified the assumptions of
normality, homogeneity of variance, and independence. Data were analyzed using a p
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value of .05 or below to determine statistical significance. I also noted the effect size of
the analysis results.
For RQ2 and RQ3, a multiple linear regression analysis was conducted to
determine if there was any relationship between remission outcomes, as measured by
MADRS uniform for each inflammatory biomarker. However, for RQ3, the variables
were mediated through age, race, or gender (see Table 2). An analysis of the descriptive
statistics of the sample was conducted, including measures of central tendency. To test
the hypotheses, a multiple linear regression analysis was conducted using SPSS. The
output data were analyzed to determine that the data met all assumptions necessary to
produce an accurate analysis, namely, independence, homogeneity of variance, and
normality. Once the assumptions were met, the results of the linear regression test were
analyzed. The analysis was repeated as necessary to identify any mediating variables, as
prompted by the significance of the identified relationships (Newsom, 2015).
Table 2
Research Question Analysis
RQ#
1

Type of
Analysis
One-way
ANOVA

2

linear
regression

3

linear
regression

Descriptive
Stats
Sample size,
standard
deviation, mean
Sample size,
standard
deviation, mean
Sample size,
standard
deviation, mean

Hypothesis Testing

Posthoc Analysis

F statistic

N/A

standardized and
unstandardized slope,
R2
standardized and
unstandardized slope,
R2

N/A

N/A
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Threats to Validity
External Validity
A threat to the external validity of this study was the administration of CP607,927 and its subsequent dismissal as ineffective. The clinical trial was stopped
because the criteria for cessation due to futility were met (ClinicalTrials.gov, 2013).
Consequently, it was not known what the influence of the drug had on the variables
measured in this study, other than being deemed ineffective as an enhancement to
antidepressant therapy. However, because the drug was deemed ineffective, the data were
interpreted with that ineffectiveness in mind. CP-607,927 was not considered as an
influential factor of the measured variables included in this study.
Internal Validity
The use of secondary data might pose as a threat to the internal validity of the
study. Data gathered for a different purpose to answer a different research question could
cause a misinterpretation of the variables, the measurement of those variables, and the
interpretation of the data (Kimberlin & Winterstein, 2008). However, this threat to
validity was mitigated by researching and understanding how the data were collected, the
purpose for which these were collected, and the measurement and representation of the
variables documented within.
Construct Validity
The construct of depression in this study could be perceived as a threat to the
statistical conclusion validity in this study. There were several types of depressive
disorders, including major depression, persistent depressive disorder, psychotic
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depression, postpartum depression, seasonal affective disorder, and bipolar disorder
(NIMH, 2016a). However, the data set used for this study included only participants
suffering from MDD. This threat to construct validity was considered when making
generalizations about depression and inflammatory biomarkers based on the data
contained herein.
Ethical Procedures
The ethical concerns for this study were limited because this study involved the
use of an archived secondary data set, containing no personally identifiable information
of participants. Prior to conducting the study, permission was obtained from the Walden
University Institutional Review Board (IRB; approval number 12-27-16-0280750).
Data received from Pfizer, Inc. were stored on an external electronic storage
device and a laptop computer, which only I could access. The laptop and external storage
device were kept in a locked safe in the researcher’s home, when not being used for the
study. Data provided would not contain any identifying information of the participants.
Moreover, I would not release or disclose any information that was previously
undisclosed and confidential (ClinicalTrials.gov, 2013).
Summary
The problem researched by this study was the relationship between inflammatory
biomarkers and treatment efficacy for depression. The purpose of this quantitative
secondary data analysis was to determine if there were a relationship between
inflammatory biomarkers and treatment efficacy in persons diagnosed with depression
who demonstrated a previous lack of remission and, if so, to what extent. The research
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design and methodology were selected to address the study problem, purpose, and related
research questions.
This chapter included details relating to the research methodology and design. A
quantitative secondary data analysis of an existing dataset from a sponsored
experimental, randomized, double-blind, placebo-controlled, and IRB-approved clinical
trial was selected to examine the relationships between inflammatory biomarkers and
depression treatment efficacy. The data set included data from 297 participants in a
clinical trial who suffered from MDD and received antidepressant treatment for their
disorder. The data were analyzed using ANOVA and linear regression. This chapter also
included addressing the threats to the validity of the study and the ethical procedures
taken by the researcher.
The next chapter contains the statistical results of the study. Chapter 4 includes a
detailed description and explanation of the data set used. The chapter concludes with an
explanation of the results from the statistical analysis.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to determine if there was a relationship
between inflammatory biomarkers and treatment efficacy in persons diagnosed with
depression who demonstrated a previous lack of remission. Eligible participants included
men and women between the ages of 18 and 65 years who were receiving ongoing
antidepressant therapy at the time of screening, including escitalopram, citalopram,
fluoxetine, paroxetine controlled-release, and sertraline. The data used for analysis were
from a clinical study conducted by Pfizer, Inc. (ClinicalTrials.gov Identifier:
NCT01098240) between June 2010 and September 2011. The study was an experimental,
randomized, double-blind, placebo-controlled, and IRB-approved clinical trial that
provided information relating to studies contained in the registry, including the study
protocol, the purpose of the study, recruitment status, and the eligibility criteria for
participants.
The outcome/dependent variable measured depression remission, and the
independent variables were adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα with three
mediating variables: age, race, and gender. A correlation analysis was conducted to
address the first research question to determine if a difference existed between
inflammatory biomarkers and treatment efficacy in persons diagnosed with depression
who had demonstrated a previous lack of remission, as measured by the MADRS. For
Research Questions 2 and 3, multiple linear regression analyses were conducted to
determine if any relationship occurred between remission outcomes, as measured by
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MADRS uniform for each inflammatory biomarker in persons diagnosed with depression
who had demonstrated a previous lack of remission, as measured by the MADRS.
However, for the third research question, the variables were mediated through age, race,
or gender.
In this chapter, I present the results of the data analysis methods following the
collection and organization of the data, including details on the research questions and
hypotheses, a description of the sample used for statistical analysis, and an exploration of
the statistical tests used to observe the research questions and hypotheses. The chapter
concludes with an overall summary of the findings.
Research Questions and Hypotheses
Based on the immune-cytokine POD and lack of research on inflammatory
biomarkers in mental health, the following research questions and associated hypotheses
were included:
RQ1: Is there any relationship between inflammatory biomarkers, including
adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα and treatment efficacy, in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H1o: There is no relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
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H1a: There is a relationship between inflammatory biomarkers and treatment
efficacy in persons diagnosed with depression who have demonstrated a previous lack of
remission, as measured by the MADRS.
RQ2: Is there any relationship between remission outcomes, as measured by
MADRS, uniform for each inflammatory biomarker in persons diagnosed with
depression who have demonstrated a previous lack of remission, as measured by the
MADRS?
H2o: There are no relationships between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
H2a: There is a relationship between uniform remission outcomes for each
inflammatory biomarker in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS.
RQ3: Is there any relationship between treatment response, as measured by the
MADRS, and inflammatory biomarkers mediated through age, race, or gender in persons
diagnosed with depression who have demonstrated a previous lack of remission, as
measured by the MADRS?
H3o: There is no relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
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H3a: There is a relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
Data Collection
Timeframe for Data Collection
The data were previously collected and readily available from Pfizer Inc.
Recruitment of study participants was not applicable because the data were initially
collected for other research purposes (i.e., Pfizer-sponsored clinical trial identified as
Protocol A3331017 [NCT01098240], entitled A Study of the Efficacy and Safety of CP601,927 Augmentation of Antidepressant Therapy in Major Depression) by Pfizer Inc.
between June 2010 and September 2011. A data access agreement was executed with
Pfizer Inc. to acquire the data, which were extrapolated from Pfizer’s main internal study
database. There were no discrepancies in data collection from the plan presented in
Chapter 3.
Demographics
The sample for this study consisted of 107 participants, who were diagnosed with
MDD without psychotic features, with the duration of the current episode of MDD being
at least 8 weeks prior to enrollment in the study. Participants were required to receive
ongoing treatment using ADT at the time of screening, including escitalopram,
citalopram, fluoxetine, paroxetine controlled-release, and sertraline. Otherwise, the
participants had to be medically healthy. Table 3 shows a summary of demographics for
the study participants: female (77.8%, n = 83) and 22.4% (n = 24) male; and White
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(86.0%, n = 92), with 13.7% (n = 14) Black; and 0.9% (n = 1) of mixed race. Average
age at baseline was 46.69 years (SD = 11.21), and average body mass index was 32.94
(SD = 7.94).
Table 3
Summary of Demographics (n = 107)
Gender
Male
Female
Race
White
Black
Other (Mixed Race)
Age (Years) at Baseline
Body Mass Index

N

Percent

24
83

22.4%
77.8%

92
14
1
Mean
46.69
32.94

86.0%
13.1%
0.9%
SD
11.21
7.94

Study Variables
The independent variables for this study were inflammatory biomarkers:
adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα. The dependent variable was the
remission outcome, as measured by the MADRS. The change in MADRS total value
from baseline was used for all statistical analyses. Mediating variables included age, race,
and gender. Table 4 shows a summary of the independent and dependent variables, where
adiponectin ranged from 4 to 58 ug/ML, with an average of 16.02 (SD = 9.02). Hs-CRP
ranged from 0.2 to 8.5 mg/L, with an average of 3.98 (SD = 3.03). Leptin ranged from 0.4
to 88 mg/ML, with an average of 26.8 (SD = 20.81). Given the large standard deviation
(relative to mean) for leptin, the median (IQR) value was 23.0 (9.0 – 38.4). IL1-β ranged
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from 1.30 to 3.31, with an average of 1.35 (SD = 0.26). IL6 ranged from 0.96 to 40.91,
with an average of 2.78 (SD = 4.34). TNFα ranged from 0.64 to 9.27, with an average of
2.06 (SD = 1.34). The dependent variable, remission outcome measured by change in
MADRS from baseline, ranged from -31 to 19, with an average of -8.38 (SD = 9.10). To
determine if a change in MADRS was clinically meaningful, a one-sample t-test was
performed to determine if the sample average of -8.38 was significantly different from
10. I found that this sample’s remission outcome was clinically meaningful (t = -20.59, p
< 0.0001). Given these results, 49.53% (n = 53) of the patients had a remission outcome
of -8.38 or lower. In addition, the median (IQR) change in MADRS from baseline was 7.0 (-15.0 – -1.0). Where 49.53% (n =53) of patients were below this median, and
50.47% (n = 54) were the same or above this median.
Table 4
Summary of Study Variables
Independent Variables
Adiponectin (ug/ML)
hs-CRP (mg/L)
Leptin (mg/ML)
IL1-β
IL6
TNFα
Dependent Variable
Remission Outcome (Change in
MADRS From Baseline)

Mean

Median

SD

Min

Max

16.02
3.98
26.80
1.35
2.78
2.06

14.00
2.90
23.00
1.30
1.58
1.89

9.02
3.03
20.81
0.26
4.34
1.34

4.00
0.20
0.40
1.30
0.96
0.64

58.00
8.50
88.00
3.31
40.91
9.27

-8.38

-7.00

9.10

-31.00

19.00

Generalizability
The patient population selected for research study was considered representative
of the broader population, as participants were outpatients, aged 18 to 65 years, who had
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a primary current diagnosis of MDD without psychotic features and receiving ongoing
ADT with an SSRI without an adequate response to treatment. Inflammatory biomarkers
can relate to the heterogeneity within the clinical diagnosis of MDD. Within the defined
screening criteria for the research study, there was demonstrated variety in the sample, as
participants met screening criteria; however, their inflammatory biomarker levels and
depression treatment outcomes differ. There may be a minority of MDD patients within
the sample who may be refractory to the treatment, irrespective of inflammatory
biomarker measurement. This finding reflected a probable homogeneous subgroup of
pathophysiology as related to the general MDD population.
Prediction of efficacy outcomes in patients with varying levels of inflammatory
biomarkers at baseline may present limitations in the generalizability of the research
study findings to the overall population of those diagnosed with MDD. Conversely, these
inflammatory biomarkers informed the relationship between the heterogeneity,
pathophysiology of MDD, and the ability of patients to demonstrate efficacy. This might
inform the identification of MDD subtypes and advance treatment selection.
Treatment Administration
The treatment was administered, as specified in the original Pfizer-sponsored
clinical trial. There were no challenges that prevented planned implementation, as
described in Chapter 3. Because this research study was a quantitative secondary data
analysis from an existing dataset, no adverse events (AEs) were noted, as this was not
applicable. The most common adverse events in the original Pfizer-sponsored clinical
trial in participants who received interventional treatment versus placebo were headache
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(20.8% vs 14.1%) and nausea (14.3% vs 14.1%; Fava et al., 2015). Additionally, there
was no differentiation between the percentages of participants who permanently
discontinued from the original Pfizer-sponsored clinical trial because of AEs in the
interventional treatment group (3.9%) versus the placebo group (3.5%), respectively
(Fava et al., 2015).
Results
Model Assumptions
To explore the research questions, correlation and multiple linear regression
analyses were used. When using these methods, there were several assumptions that must
be true for the tests to be valid. Verification of the assumptions of normality,
homogeneity of variance, and independence occurred. To test that the data met these
assumptions, Shapiro-Wilk tests and an examination of skewness and kurtosis values
were observed for normality. Shapiro-Wilk statistic p-values > 0.05 (nonsignificant) and
skewness/kurtosis values between -3 and 3 were indications of a normal distribution.
Additionally, following each regression model, for the assumptions of homogeneity of
variance and independence, an observation of a plot of the residuals by fitted values was
made. In the results of the Shapiro-Wilk tests and Skewness/Kurtosis observations, I
found that there were some study variables that did not fully meet all normality
assumptions (see Table 5). For the correlation analysis, both Pearson (parametric) and
Spearman (nonparametric) correlations were calculated.
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Table 5
Shapiro-Wilk and Skewness/Kurtosis Checks for Normality
Adiponectin
hs-CRP
Leptin
IL1-β
IL6
TNFα
Remission Outcome

SW Statistic
0.83
0.86
0.92
0.19
0.40
0.84
0.98

P-value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.054

Skewness
1.98
0.42
0.91
6.27
6.78
1.99
-0.21

Kurtosis
5.30
-1.40
0.35
40.93
56.82
7.43
-0.10

Research Question 1
To explore Research Question 1, Pearson’s correlation was used to determine if
there was a difference between inflammatory biomarkers (independent variables) and
treatment efficacy (dependent variable) in persons diagnosed with depression who have
demonstrated a previous lack of remission, as measured by the MADRS. In the results of
the correlations (see Table 6), I found that IL6 was the only biomarker that was
significantly associated with change in MADRS total score from baseline (Spearman
Correlation = 0.24, p = 0.013). An increase in IL6 correlated with a mild to moderate
increase in remission outcome. All other biomarkers were not statistically significant.
The null hypothesis could be rejected for IL6, concluding that there was a relationship
between IL6 and treatment efficacy in persons diagnosed with depression who have
demonstrated a previous lack of remission, as measured by the MADRS.
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Table 6
Pearson’s Correlations with Remission Outcome

Adiponectin
hs-CRP
Leptin
IL1-β
IL6
TNFα

Pearson
Correlation
-0.11
-0.03
0.04
-0.04
0.32
0.11

Pearson
p-value
0.279
0.738
0.665
0.681
0.001
0.282

Spearman
Correlation
-0.01
-0.05
0.10
-0.02
0.24
0.11

Spearman
p-value
0.932
0.638
0.319
0.838
0.013
0.257

Research Question 2
To explore Research Question 2, several simple linear regression analyses were
conducted to determine if there was any relationship between remission outcomes, as
measured by MADRS uniform for each inflammatory biomarker in persons diagnosed
with depression who have demonstrated a previous lack of remission, as measured by the
MADRS. Similar to the correlation analysis, in the results of the regression models (see
Table 7), I found that IL6 was the only biomarker that significantly predicted remission
outcome (t = 3.43, p < 0.05). For everyone unit increase in IL6, the change in MADRS
from baseline increased by 1.29. In addition, 10.4% of the amount of variability in the
outcome can be attributed to IL6. None of the other biomarkers significantly predicted
remission outcome. I could reject the null hypothesis for IL6, concluding that there was a
relationship between uniform remission outcomes for IL6 in persons diagnosed with
depression who demonstrated a previous lack of remission, as measured by the MADRS.

82
Table 7
Simple Linear Regressions for Each Inflammatory Biomarker by Remission Outcome
Adiponectin
hs-CRP
Leptin
IL1-β
IL6
TNFα
Note. *p < 0.05

B
-0.11
-0.01
0.02
-1.42
1.29
0.72

SE(B)
0.10
0.30
0.04
3.46
0.38
0.67

β
-0.11
0.74
0.04
-0.04
0.32
0.11

t
-1.09
-0.34
0.43
-0.41
3.43*
1.08

R2
0.011
0.001
0.002
0.002
0.104
0.011

Research Question 3
To explore Research Question 3, several multiple linear regression analyses were
conducted to determine if there was any relationship between remission outcomes, as
measured by MADRS uniform for each inflammatory biomarker in persons diagnosed
with depression who have demonstrated a previous lack of remission, as measured by the
MADRS, while checking for mediation of age, race, and gender. Results of each
regression (see Tables 8 through 13) showed that age, race, and gender did not mediate
any of the relationships between the biomarkers and remission outcome. I could see that
the associations between each biomarker and the outcome have not changed when age,
race, and gender were added to the model. IL6 remained the only biomarker significantly
associated with change in MADRS total score from baseline (t = 3.50, p < 0.05). These
results showed that the null hypothesis failed to be rejected, concluding that there was no
relationship between treatment response and inflammatory biomarkers mediated through
age, race, or gender in persons diagnosed with depression who demonstrated a previous
lack of remission, as measured by the MADRS.
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Table 8
Multiple Linear Regressions for Adiponectin by Remission Outcome, Adjusting for Age,
Gender, and Race
B
Adiponectin
-0.08
Age
-0.05
Gender (Male)
-3.07
Race (Black)
-2.58
Race (Other)
-1.27
Note. *p < 0.05, Model R2 = 0.04

SE(B)
0.10
0.08
2.26
2.71
9.34

β
-0.08
-0.06
-0.14
-0.10
-0.01

t
-0.81
-0.63
-1.36
-0.95
-0.14

Table 9
Multiple Linear Regressions for hs-CRP by Remission Outcome, Adjusting for Age,
Gender, and Race
B
hs-CRP
-0.08
Age
-0.06
Gender (Male)
-3.46
Race (Black)
-2.18
Race (Other)
-1.69
2
Note. *p < 0.05, Model R = 0.04

SE(B)
0.30
0.08
2.21
2.67
9.43

β
-0.03
-0.08
-0.16
-0.08
-0.02

t
-0.27
-0.78
-1.57
-0.82
-0.18

Table 10
Multiple Linear Regressions for Leptin by Remission Outcome, Adjusting for Age,
Gender, and Race
B
Leptin
0.03
Age
-0.06
Gender (Male)
-3.79
Race (Black)
-1.89
Race (Other)
-0.58
2
Note. *p < 0.05, Model R = 0.04

SE(B)
0.04
0.08
2.26
2.71
9.45

β
0.06
-0.07
-0.17
-0.07
-0.01

t
0.60
-0.70
-1.68
-0.70
-0.06
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Table 11
Multiple Linear Regressions for IL1-B by Remission Outcome, Adjusting for Age,
Gender, and Race
B
IL1-B
-0.59
Age
-0.06
Gender (Male)
-3.46
Race (Black)
-2.19
Race (Other)
-1.38
Note. *p < 0.05, Model R2 = 0.04

SE(B)
3.56
0.08
2.22
2.68
9.36

β
-0.02
-0.08
-0.16
-0.08
-0.01

t
-0.17
-0.73
-1.56
-0.82
-0.15

Table 12
Multiple Linear Regressions for IL6 by Remission Outcome, Adjusting for Age, Gender,
and Race
B
IL6
1.33
Age
-0.10
Gender (Male)
-3.54
Race (Black)
-1.27
Race (Other)
0.08
2
Note. *p < 0.05, Model R = 0.14

SE(B)
0.38
0.08
2.08
2.53
8.84

β
0.33
-0.12
-0.16
-0.05
<0.01

t
3.50*
-1.23
-1.70
-0.50
0.01

Table 13
Multiple Linear Regressions for TNFα by Remission Outcome, Adjusting for Age,
Gender, and Race
B
TNFα
0.61
Age
-0.07
Gender (Male)
-3.23
Race (Black)
-2.09
Race (Other)
-1.16
2
Note. *p < 0.05, Model R = 0.04

SE(B)
0.68
0.08
2.22
2.66
9.33

β
0.09
-0.09
-0.15
-0.08
-0.01

t
0.89
-0.84
-1.46
-0.79
-0.12
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Summary
The main purpose of this quantitative study was to determine if there was a
relationship between inflammatory biomarkers and treatment efficacy in persons
diagnosed with depression who demonstrated a previous lack of remission and, if so, to
what extent. Results of the analyses showed that IL6 significantly correlated and
predicted remission outcome, as measured by change in MADRS total score from
baseline. None of the other biomarkers significantly associated with remission outcome.
Additionally, there was no relationship between treatment response and inflammatory
biomarkers mediated through age, race, or gender in persons diagnosed with depression
who have demonstrated a previous lack of remission, as measured by the MADRS.
Chapter 5 consists of interpretations of the findings, limitations of this study,
recommendations for future studies, and implications. I discuss in more detail what the
data mean for the current study, the impact on social change, and how the results can be
used for future studies pertaining to the relationship between inflammatory biomarkers
and treatment efficacy in persons diagnosed with depression who demonstrated a
previous lack of remission.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The primary purpose of this quantitative study was to assess the influence of
inflammatory biomarkers on treatment efficacy in persons diagnosed with depression,
who have previously demonstrated lack of remission. The study was conducted on
participants between the ages of 18 to 65 years, who were receiving ADT, including
escitalopram, citalopram, fluoxetine, paroxetine controlled-release, and sertraline at the
time of screening. Remission outcome was measured in terms of change in the MADRS
from baseline. I found that indicated that IL-6, one of the biomarkers investigated in the
study, positively related to remission outcome. The other biomarkers studied, namely,
adiponectin, hs-CRP, leptin, IL1-β, and TNFα, failed to show the same significant
relationship. In addition, I found that age, gender, and race did not act as mediators in the
relationship between the biomarkers and remission outcomes.
I used the theoretical backdrop of the immune-cytokine POD (Smith, 1997),
primarily because the framework provided a novel medium of exploring the causes of
depression by using a cytokine based disease model (Roy & Campbell, 2013; Smith,
1997). Psychosocial stressors associated with depression, preceding or leading to MDD
(Miller & Raison, 2016) could activate inflammatory biomarkers. I found that physical
processes, such as secretion of cytokines (biomarkers) in patients diagnosed with
depression, could have affected the remission outcomes. An increase in IL6 correlated
with a mild to moderate increase in remission outcome of patients diagnosed with
depression. Perhaps the greatest advantage of using this theoretical framework was that it
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helped fill the gaps in understanding the interconnected nature of the physical and mental
processes.
Interpretation of the Findings
The following sections of this chapter include interpretation of the study’s results
in the light of existing literature. Additionally, I discuss the limitations of the research, as
well as the implications and impact for social change, and conclude with
recommendations for future studies.
Inflammatory Biomarkers and Treatment Efficacy
The first research question stated the following: Is there any relationship between
inflammatory biomarkers, including adiponectin, hs-CRP, leptin, IL1-β, IL6, and TNFα
and treatment efficacy, in persons diagnosed with depression who have demonstrated a
previous lack of remission, as measured by the MADRS? I found that only biomarker IL6
positively correlated to remission outcome. I found that IL6 significantly associated with
change in MADRS score from baseline (Pearson correlation= 0.32, p= 0.001), thereby
making it a mild to moderate predictor of treatment efficacy in people who were
diagnosed with depression but who had previously displayed lack of remission. I also
found that the independent variables, consisting of biomarkers adiponectin, hs-CRP,
leptin, IL1-β, and TNFα did not show any significant influence on the remission
outcomes. However, I noted that the relationship between biomarkers and depression
treatment outcomes were correlational, thereby making it hard to illustrate causality.
In spite of the correlational nature of the results, these finding were noteworthy,
as these remained consistent with existing research in the field that showed
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proinflammatory biomarkers predicted depression. The result that biomarker IL6 was
significantly related to treatment efficacy for depression supported earlier researchers
who established an association between illnesses with inflammatory conditions and
depression (Dowlatia et al., 2010; Sua, 2012; Walker et al., 2014). Furthermore, this
finding provided support of the role of IL6 in the etiology of depression. Fonseka,
McIntyre, Soczynska, and Kennedy (2015) emphasized how IL6 associated with
pathophysiology of MDD, as well as several inflammatory and autoimmune diseases.
Fonseka et al. pointed out that pharmacotherapy primarily targeted neurochemical
pathways for treating MDD, which revealed low remission rates with high probability of
recurrence. Thus, the findings have clinical significance in the diagnosis of MDD and its
treatment.
Not all the biomarkers showed a significant relationship to remission outcome,
which was also consistent with extant literature (Smith, 1997). Cytokines, which were
present in every human body, could be produced with the right stimulation at any given
time. However, the secretion of cytokines did not necessarily result in depression. I found
that IL6 had a significant correlation with remission outcome, which could help in
distinguishing MDD patients from other patient groups demonstrating similar clinical
qualities and characteristics. It could also predict the degree to which IL6 influences
treatment efficacy for depression. I extended the earlier research (Krishnadas &
Cavanagh, 2012) by showing that one of the biomarkers, IL6, could moderately predict
remission outcome. Krishnadas and Cavanagh (2012) tried to understand why treatment
for depression was effective for some and not others by looking at inflammatory
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biomarkers. Maes, Kubera et al. (2012) also postulated that inflammatory biomarkers
might be underlying depression.
Maes, Kubera et al. (2012) postulated that the biomarkers might also play a role in
how people with depression respond to interventional therapy. Maes, Kubera et al.
revealed that the correlational association between biomarker IL6 and remission outcome
had connotations for clinicians and therapists who could use the information to evaluate
how patients will respond to treatments. Elevated IL6 levels could be used in the
diagnosis of depression, which would add value to current diagnostic methods (Lopresti
et al., 2014) and treatment options that often culminated to a trial and error process (Chan
et al., 2016). Considering the research was conducted on patients diagnosed with
depression who had previously shown lack of remission, the results could be used for
evaluating why some patients do not respond to certain treatments and therapies. This
study provided a more IL6 targeted treatment approach for diagnosing patients with
MDD and designing therapies and drugs that might be more effective in treating
depression. In addition, it could provide information on more standardized ways of
approaching depression, rather than a trial and error approach.
I confirmed the association between IL6 and depression treatment outcomes,
which could also contribute to finding novel ways for treating depression. The IL6
biomarker could be used in predicting how patients would react to ADTs. Researchers
indicated that the inflammatory biomarkers, such as adiponectin, CRP, leptin, IL1-β, IL6,
and TNFα often led to lack of response to therapy and reduction of the effectiveness of
antidepressants (English et al., 2010; Raison et al., 2013; Strawbridge et al., 2015).
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One of the concerns that arose from lack of proper diagnosis and apposite
treatment options was that patients often did not respond to the treatment. Ruland et al.
(2016) and Sua (2012) postulated that when patients who were nonresponsive to
antidepressants and treatment options were repeatedly exposed to unsuccessful
treatments, they often became treatment resistant. High levels of proinflammatory
biomarkers at baseline, especially IL6, could help determine lack of response to
antidepressants. Under those circumstances, I suggested that a more targeted approach for
the population could improve remission results. With the selective inhibition of IL6, the
putative effects of antidepressants might be fully used.
Inflammatory Biomarkers and Remission Outcome
The second research question stated the following: Is there any relationship
between remission outcomes and inflammatory biomarkers, as measured by MADRS, in
persons diagnosed with depression who have demonstrated a previous lack of remission?
The results corroborated the findings of the correlational analysis of the previous research
question and showed IL6 was the only biomarker that influenced remission outcome (t =
3.43, p < 0.05), namely that there was a relationship between the presence of biomarker
IL6 and remission outcomes in people diagnosed with depression who previously failed
to show proper remission. For every unit increase in IL6, the MADRS score from
baseline increased by 1.29. In fact, 10.4% variability in the outcome could be accounted
by the presence of IL6. Other biomarkers, including adiponectin, hs-CRP, leptin, IL1-β,
and TNFα on remission outcomes, were not statistically associated with remission.
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In my study results, I undermined the importance of understanding the roots of
depression for improving treatment outcomes. Kessler et al. (2016) pointed to the
heterogeneous nature of depression, making it difficult to be conceptualized and treated
without understanding its origin. Gaynes et al. (2009) focused on treatment resistant
depression and found that remission was a complex process, involving several steps.
Gaynes et al. highlighted the need for better diagnosis of the improved regiments of
medications. This study highlighted how the presence of certain biomarkers, such as IL6,
could modify remission outcomes, thereby providing a probable cause for the differences
in how patients responded or failed to respond to medications and therapies.
The study had clinical significance because it could be used in developing
individualized treatment options for depression based on their biological composition and
ways in which they responded to certain treatments. Redei et al. (2014) underscored the
importance of predictive variables in predicting remission outcomes. In spite of the
presence of multiple interventional pharmaceutical therapies targeting depression, the
remission outcomes following those treatments were unsatisfactory (Hashimoto, 2015;
Slavich & Irwin, 2014). The treatment options for depression varied in efficacy. Thus, the
identification of the biomarker, namely IL6 as one of the variables that affected remission
outcomes, could help further research on improving treatment outcomes by providing
more proper assessment and individualized treatments. The results of this study can be
used for increasing the chance of successful treatment of patients diagnosed with
depression. The relationship between biomarkers and depression might help in
identifying individuals at risk for depression.
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Responses Mediated by Age, Race, and Gender
The third research question asked the following: Is there any relationship between
treatment response, as measured by the MADRS, and inflammatory biomarkers mediated
through age, race, or gender in persons diagnosed with depression who have
demonstrated a previous lack of remission, as measured by the MADRS? The results
from the multiple linear regression analyses conducted supported the null hypothesis,
indicating age, gender, and race were not mediating the relationships between the
biomarkers and remission outcomes, as measured by MADRS. When age, race, and
gender were added to the model, I found that the relationship between each biomarker
and remission outcome did not account for any statistical significance, except for IL6,
which showed a change in MADRS total score from the baseline (t = 3.50, p < 0.05). I
stopped reviewing here. Please go through the rest of your chapter and look for the
patterns I pointed out to you. I will now review your references.
The study corroborated Wolitzky-Taylor et al. (2012), in which the researchers
found that factors, such as race, gender, age, comorbidity, or severity of the disorder, did
not predict treatment outcomes in their investigation of the effectiveness of cognitive
behavioral therapy (CBT) in comparison to acceptance and commitment therapy (ACT)
for treating anxiety disorders. Hauser et al. (2002) investigated whether interferon (IFN)
induced MDD could be effectively treated with antidepressants. Hauser et al. also found
that history of MDD, substance use, age, or gender did not mediate treatment outcome.
Contrary to the findings of the current study, some studies found age as an
important mediator in the relationship between biomarkers and treatment outcomes for
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depression (Allison et al., 2014; Luby, 2013; Mills et al., 2013). It must be noted that this
study only focused on individuals ranging in age between 18 to 65 years. The other
researchers that found age to mediate the association of biomarkers to treatment
outcomes often focused on age groups beyond the scope of this study (Allison et al.,
2014; Luby, 2013; Mills et al., 2013). Luby (2013) found that children as young as 3
years of age showed signs of depression and discovered that detection and early
intervention was essential to ensure long-term effects for these young children. Allison et
al. (2014) also pointed to the importance of early detection and proper treatment of
depression in children to prevent further deterioration of condition. In addition, Mills et
al. (2013) found that adolescents diagnosed with depression illustrated certain agespecific immune and inflammatory system characteristics. Mills et al. had also found that
factors, such as neurodevelopment, hormones, stress, and trauma, affected the role played
by cytokines in adolescents with depression.
I also did not find race as a mediating factor in the relationship between
biomarkers and remission outcomes in patients diagnosed with depression, who had
illustrated lack of remission. Hauser et al. (2002) found that significantly lower number
of African Americans had depression. Similar to the other mediating variables of age and
race, the current results did not find gender to mediate the connection between
biomarkers and depression remission outcomes.
Existing research, focusing on gender as a mediating factor in treatment outcome,
were inconclusive. Hauser et al. (2002) and Wolitzky-Taylor et al. (2012) did not find
that comorbidity, race, gender, age, or severity of the disorder was predictive of treatment
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outcomes. However, Miller and Raison (2016) found that depression in women increased
significantly when compared to men, which became even more pronounced during the
reproductive years.
Miller and Raison (2016) have shown also shown gender as a mediating factor
affecting the relationship between biomarkers and treatment outcomes. Studies have
revealed women were more prone to the effects of inflammation on behavior, resulting in
more significant symptoms of depression (Miller & Raison, 2016). Inflammation might
have negative effects on fertility and lactation, both of which could partially explain the
higher incidence of depression among women compared to among men (Miller & Raison,
2016). Being prone to depressive symptoms caused by inflammation, women might also
have been provided with more protection to fight infection and heal wounds, as well as
avoiding illness. The lack of evidence of age, race, and gender, as influencing the
association between treatment outcomes and biomarkers, warranted further research.
This quantitative study determined, to some extent, the relationship between
inflammatory biomarkers and treatment efficacy in persons diagnosed with depression
who previously demonstrated lack of remission. I showed that only biomarker IL-6
correlated to treatment efficacy and that age, race, and gender did not mediate the
aforementioned correlation.
Limitations
The scope of this research study remained limited to the variables and associated
data from a clinical study conducted by Pfizer, Inc. between June 2010 and September
2011, on outpatients between the ages of 18 and 65 years. I considered correlations of the
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specific biomarkers, namely, adiponectin, C-reactive protein (hs-CRP), leptin, interleukin
1-β (IL1-β), interleukin 6 (IL6), and tumor necrosis factor-α (TNFα), with depression
treatment efficacy and depression remission outcomes, as moderated by the demographic
factors of age, race, and gender. The results from this secondary data did not necessarily
carry over to the larger patient-population suffering from depression. There were no
discrepancies in data collection from the plan, as it was restricted to secondary data from
the original study conducted by Pfizer, Inc.
Second, I assumed that focusing only on the six specific biomarkers would prove
sufficient for the purposes of the study. However, other inflammatory biomarkers might
have related to treatment efficacy and remission outcomes, in addition to the ones that
were part of the study. Third, I applied multiple linear regression analysis, which tested
for association but not causality. Additional research was needed to help to establish a
causal relationship. Fourth, I noted that cytokines were not only present in all humans,
but these could also be produced under the right stimulation. I suggested that the
cytokines, considered in this research (INFα, TNF, IN1, etc.), have the potential to cause
depression in most but not all subjects. I had to remain cautious about generalizing the
findings to include all cytokines.
Fifth, I did not consider other factors that affected remission. For instance,
researchers indicated that the patients’ perspective influenced the state of remission
(Zimmerman et al., 2012). Thus, remission might be a subjective state. Sixth, the
conceptual framework of immune-cytokine POD (Smith, 1997) was a newer method of
looking at the role biomarkers played in depression by the presence in the brain,
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endocrine system, and immune system. As such, the validity and reliability of this
framework might be questioned (Brenner et al., 2014).
Seventh, there were other theoretical and conceptual models identified in the
study, including the affective response model (Zhang & An, 2013) and the social signal
transduction theory of depression (Slavich & Irwin, 2014). However, given that the study
depended on secondary data, the alternative conceptual models could not be evaluated.
Finally, overwhelming majority of the sample consisted of females (77.8%) and White
individuals (86%). The findings might not be generalizable to larger population. Further
research should include a more representative sample.
Recommendations
I defended the immune-cytokine MOD theory by showing how cytokines (the
biomarkers in the study) could predict treatment efficacy and outcome for depression. I
showed that biomarker IL-6 significantly correlated to remission outcome, whereas the
other biomarkers, such as adiponectin, hs-CRP, leptin, IL1-β, and TNFα, were not
correlated. Future researchers could focus on causation and provide concrete evidence of
the relationship between biomarkers and remission outcomes.
Future researchers could also be conducted to advance the theory by probing
deeper into the physical and mental processes that influence the development and
remission depression. More studies are needed to support the validity of the relatively
new alternative approach of studying the effects of cytokines on depression treatment
outcomes through the immune-cytokine MOD theory. Further, researchers could also
identify the degree to which specific biomarkers that influence remission outcomes.
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Longitudinal studies spanning across several years might also provide more accurate data
about the lengthy process of remission. Future researchers investigating the influence of
biomarkers on antidepressants might yield better results in pharmacotherapy. Miller et al.
(2003) found that depression symptoms and activation of inflammatory response could
potentially modify the remission outcome for depression treatments. Better drug
development research could pave the way for improving treatment efficacy and
outcomes.
In spite of the widespread prevalence of depression in patients, irrespective of
their age, gender, or race, treatment options lagged behind the demand for treatment. The
available treatment options often resulted in a trial and error process due to the lack of
proper research on treatment efficacy. The depression treatment outcomes failed to
achieve the desired remission goals. The above scenario warranted a better look at
empirical research and findings to optimize interventional pharmaceutical therapies for
patients. Researchers could use the data from the current study, as well as similar studies,
to inform clinicians and therapists to provide the best treatments and medications.
Future researchers should also research specific age groups and assess the
implications of depression. There was a scarcity of research on how depression affected
young children and the treatment options that could ensure remission. Depression in
elderly people was misdiagnosed, leading patients receiving incorrect treatment (Karlsson
et al., 2016). Future researchers should educate people about the heterogeneity of
depression and how it yielded adverse effects in terms of symptoms, decreased
productivity, increased morbidity, and suicidal tendencies (Wray et al., 2012). Future
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researchers should design studies concentrating on the adverse effects of depression and
find the underlying factors. Reliable and valid data could help remove some of the stigma
associated with depression and usher in social change.
Implications
The results of the study have important implications for positive social change.
Depression proved a heavy burden on individuals, families, and society. Wray et al.
(2012) emphasized how depression had adverse effects on individuals in terms
symptomatology, decreased productivity, and increased sense of morbidity. The stigmas
associated depression often made it harder for patients to seek professional help (Czyz et
al., 2013). Depression was responsible for the high suicide rates (Wray et al., 2012).
Billions of dollars were spent annually in identifying and treating depression (Greenberg
et al., 1993). In spite of the proliferation of depressive disorders in people, the efficacies
of available treatments remained limited (Gaynes et al., 2009).
The results from the current study could help developing early intervention
strategies for decreasing incidence of suicides. Researchers showed that MDD patients
with suicide ideation display high levels of the IL6 and CRP (Fonseka et al., 2015). IL6
has been the most dominant cytokine that has been linked with suicidal ideation and in
fatal as well as nonfatal suicide cases (Mormile, 2016). This study could benefit
intervention therapists by indicating the role of IL6 in inflammation and its subsequent
influence on the pathophysiology of MDD and showing that treatment targeting IL-6
could yield alleviation from suicidal tendencies.
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The findings also have significant implications for improving remission outcomes
by identifying high-risk individuals prior to any depressive episode. Bredt et al. (2015)
emphasized the importance of distinguishing at-risk individuals and factors that triggered
the expression of the disease might help in incorporating avoidance practices that would
delay or even stem the disease from occurring. Some of the ways that these could be
achieved was by screening for IL6, blood sampling, to ascertain the association between
inflammatory cytokines and behavioral symptoms (Felger et al., 2013). The findings
would help identify individuals, who might fail to respond to treatment due to presence of
higher levels of IL6.
I, by using a cytokine based approach for finding a resolution for depression
related issues, provided an enhanced platform for identifying and stratifying patients with
respect to bio-signatures and phenotypic traits. This approach was more biology based
rather than symptom based categorization, as symptom based grouping could lead to
overlapping and clubbing of patients with diverse illnesses but similar behavioral
symptoms.
I, along with other extant research, could provide information on ways to detect
and treat depression to improve chances of remission. Researchers showed that
depression in young children, if it remains untreated, could have severe consequences
later in life (Luby, 2013). Researchers could use the research findings to analyze the
underlying causes of depression in individuals, as well as for predicting treatment
responses. The findings could be used by clinicians to tailor treatment to address
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depression in a variety of scenarios, such as preschool children, suicidal tendencies in
adolescent depression victims, or elderly people who were misdiagnosed.
Miller and Raison (2016) showed women were more prone to the effects of
inflammation on behavior, resulting in more significant symptoms of depression, and the
symptoms became more pronounced during their reproductive years. Miller and Raison
also showed that inflammation might have negative effects on fertility and lactation,
thereby increasing the chances of depression in women (Miller & Raison, 2016).
The findings of the study have great implications in the areas of theory, research,
and practice. I advanced human models of depression by focusing on biological systems
that affect the etiology of depression. Bredt et al. (2015) demonstrated how experimental
human models, associated with mood disorders, could use biological factors of
depression to design intervention that simulate biological conditions to trigger depression
related behaviors and assess the impact. I also provided valuable insight into the
biological factors that influenced depression by revealing that production of increased
levels of IL6 could affect remission outcomes.
Another important contribution of this study to the field was that biomarker levels
could be used to select appropriate therapeutic treatments. Given that the pathogenesis of
most of mood disorders remained unclear, it was hard to deliver treatment options
tailored to individual requirements (Bredt et al., 2015). I provided data that
counterbalanced those challenges by showing how biomarker levels could help identify
interventional therapies that would demonstrate high efficacy for treatment resistant
patients.
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I analyzed the causes of depression from a relatively new perspective by looking
into the relationship between inflammatory biomarkers and its effects on remission
outcomes. It could also help clinicians and pharmaco-therapists to explore alternative
methods of treatments for optimizing outcomes. Proper diagnosis could curtail the serious
repercussions depression has on individuals, by being able to identify upfront those, who
are more likely to respond to treatment and those who might not. Individuals, who were
at risk and would not respond to the treatment, could then follow other therapies that
suited their specific needs in terms of their biological compositions.
Researchers showed that the presence of IL6 might affect clinical response to
novel therapies (Martin, Tansey, Schalkwyk, & Powell, 2015). Biomarker IL6 has the
capability of inhibiting the production of serotonin in raphe neurons, which could explain
why high levels of IL6 could influence efficacy of outcomes in therapies that are still
under development (Martin et al., 2014).
Utilizing the immune-cytokine POD theory (Smith, 1997), I provided a new
approach to understanding depression with respect to inflammatory biomarkers. I found
results that supported the immune-cytokine MOD theory by illustrating the correlation of
cytokines (i.e., biomarkers in IL-6, in the study) to treatment efficacy and outcome for
patients diagnosed with depression who have shown lack of remission. Analyzing the
results with respect to the tenets of the theory has shown how physical and mental
processes could influence treatment outcomes for depression.
I identified specific biomarkers that were both correlated (IL-6) and not correlated
(adiponectin, hs-CRP, leptin, IL1-β, and TNFα) to treatment efficacy and outcomes for
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patients diagnosed with depression. This finding might provide a more tailored list of
variables that future researchers might study. Future researchers might be able to identify
other biomarkers that affect remission outcomes.
Through the literature review, I also revealed how other factors could affect
remission outcome for depression (Zimmerman et al., 2012). Zimmerman et al. (2012)
found that remission could be subjective state that was contingent upon the patients’
perceptions. Thus, I found it necessary to view the findings of the current research, as one
possible way of analyzing treatment outcome among several others. I showed that age,
gender, and race did not act as mediators in the relationship between biomarkers and
remission outcome in patients diagnosed with depression. This finding could aid
researchers in delving deeper and finding the true implications, if any, of those factors in
the treatment of depression. I extended earlier research (Krishnadas & Cavanagh, 2012)
by showing that one of the biomarkers, IL-6, could moderately predict remission
outcome. The results could provide valuable insights into modifying pharmacotherapies
for specific subpopulations suffering from depression.
Conclusion
Depression is one of the most significant diseases afflicting individuals, leading to
considerable increase in healthcare and disability costs. It is heterogeneous—meaning, its
symptoms and effects vary on a case-by-case basis. As such, diagnosis of depression
often depends on unreliable and inconsistent symptoms. Current pharmaceutical therapies
often lag behind in achieving the desired level of recovery in patients. Even though there
are resources that address the effect of inflammatory biomarkers on depression, more
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questions need to be answered as to how these affect treatment efficacy. Researchers are
also unsure about how age, race, and sex mediate the influence of inflammatory
biomarkers on treatment efficacy and remission outcomes. While the effects of
inflammatory biomarkers are typically manifested in a person’s adolescent years, studies
regarding the severity of such impact are rare.
Due to the heterogeneity in the types of depression that inflicts patients, some
healthcare providers resort to multiple avenues of treatment simultaneously. Such
measures lead to a prolonged and chaotic treatment regime on the patient, with no certain
solution sight. The current research was conducted in the backdrop of these shortcomings
to achieve a better understanding of the following three questions:
1. How inflammatory biomarkers is related to TE.
2. If the RO are the same irrespective of the type of IB
3. If the relation between IB and TE is mediated by age, race and gender.
Using a combination of correlation analysis and multiple linear regression, I
found partial support for the three hypotheses of this study. The outcome/dependent
variable measured depression remission, while the independent variables included
adiponectin, hs-CRP, IL1-β, IL6, and TNFα. The three mediating variables included age,
race, and gender. One of the advantages of the research methods used in the study was
that I focused only on recent research, mostly restricted to those published in the last 4
years. This focus not only made the study up-to-date, but also more reliable in
understanding where research stands today and the future directions needed for
advancing the knowledge.
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As to the first question, I showed that IL6 was the only biomarker that was
significantly associated with change in MADRS total score from baseline. An increase in
IL6 was correlated with a mild to moderate increase in remission outcome. The
relationships of remission outcome and all other biomarkers were not statistically
significant. I also found that IL6 was the only biomarker that considerably predicted
remission outcome, along the lines of the previous outcome. For every one unit increase
in IL6, the change in MADRS from baseline increased by 1.29. IL6 was still the only
biomarker significantly associated with change in MADRS total score from baseline.
Finally, I observed that demographic variables (e.g., age, race, and gender) did not
mediate any of the relationships between the biomarkers and remission outcome. The
findings appeared robust, as IL6 turned out to be the only inflammatory biomarker
significantly associated with change in MADRS score from baseline. Future researchers
must use caution in generalizing the effects of the study because of the nature of
heterogeneity in the depression symptoms.
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